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Kinetisol® To Produce Amorphous Solid Dispersions With Improved In-Vitro And 
In-Vivo Performance 
 
Daniel James Ellenberger, Ph.D. 
The University of Texas at Austin, 2017 
 
Supervisor:  Robert O. Williams III 
 
KinetiSol processing is an emerging technology for processing amorphous solid 
dispersions for pharmaceutical delivery of poorly water soluble drugs. Chapter 1 reviews 
the current literate around the application of this technology and provides insights into its 
benefits to pharmaceutical product development for poorly water soluble drugs. 
In Chapter 2, KinetiSol processing was used to render amorphous the poorly water 
soluble drug vemurafenib. Vemurafenib was challenging because conventional processes 
of pharmaceutical amorphous dispersions (hot melt extrusion and spray drying) were 
unable to render formulations containing this molecule amorphous and a non-ideal solvent-
controlled coprecipitation process was utilized in production of its commercial product. 
Material generated by the KinetiSol process had particle morphology that differentiated it 
from the commercial particles. In-vitro and in-vivo performance analysis of the KinetiSol 
and commercial materials demonstrated enhanced product performance and drug exposure 
for the materials processed by KinetiSol. 
 ix 
In Chapter 3, KinetiSol processing produced a high drug load formulation of the 
anti-viral and pharmacokinetic boosting drug, ritonavir. The amorphous solid dispersion of 
ritonavir was demonstrated as amorphous and intimately mixed by sensitive analysis such 
as solid state nuclear magnetic resonance. During comparison to the commercial product 
for ritonavir, transmembrane flux analysis revealed similar permeation rates for both 
dosages. Subsequent in-vivo pharmacokinetic analysis in dogs resulted in equivalent 
exposure for the test and reference products with a small reduction in maximum plasma 
concentration. It was concluded that the tablet generated in the study could serve as a 
pharmacokinetic booster with tablet mass reduced by approximately half. 
In Chapter 4, the extent of a surprising pharmacokinetic result with a lubricant was 
investigated. The result was surprising as lubricants such as magnesium stearate are 
typically understood to hinder performance in dosage forms containing poorly soluble 
drugs and are typically avoided, but the original result showed a significant increase in 
exposure. The study evaluated several additional cases and demonstrated positive effects 
of lubricant inclusion for weak acid, neutral, and weak base example compounds. 
Additionally, the study evaluated additional components not classified as pharmaceutical 
lubricants but with similar physiochemical properties to magnesium stearate and 
demonstrated similar positive benefits for these additional compounds. 
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Chapter 1: Expanding the Application and Formulation Space of Amorphous Solid 




Due to the high number of poorly soluble drugs in the development pipeline, novel processes for 
delivery of these challenging molecules are increasingly in demand. One such emerging method 
is KinetiSol, which utilizes high shear to produce amorphous solid dispersions. The process has 
been shown to be amenable to difficult to process active pharmaceutical ingredients with high 
melting points, poor organic solubility, or sensitivity to heat degradation. Additionally, the 
process enables classes of polymers not conventionally processable due to their high molecular 
weight and/or poor organic solubility. Beyond these advantages, the KinetiSol process shows 
promise with other applications, such as the production of amorphous mucoadhesive dispersions 




There is a growing need for aqueous solubility enhancement of active pharmaceutical ingredients 
(APIs). It is estimated that approximately 70-90% of drugs in development (1, 2) and 40% of 
currently marketed products (3) are solubility challenged. These drugs fall into class II and class 
IV of the Biopharmaceutical Classification System (BCS) for which solubility enhancement can 
 2 
be used to improve oral bioavailability. In the case of BCS class IV compounds, permeability 
also presents a challenge for effective drug delivery. (4) Lipinski et al. established the rule of five 
to help predict which APIs coming out of drug discovery and development would be predicted to 
be challenging based on solubility and permeability considerations. (5) However, recent trends 
have shown that molecules coming out of development are more likely to be beyond the rule of 
five or just below the margins of the rule of five. Even though these below the margins drugs 
meet the rule of 5 criteria, they remain a challenge to develop. Within this trend, highly 
lipophilic compounds and higher molecular weight compounds are increasingly common. (6) 
Filed patent applications on drug molecules show on average higher molecular weights and 
lipophilicity than what is present in commercially approved products indicating high rates of 
attrition as products move from discovery through development. (7) These molecules tend to be 
solvation limited and benefit from the application of solubility-enabled formulations to ensure 
bioavailability. (8) These solubility-enabled formulations address the challenges of poorly 
soluble molecules by improving drug release rate and/or solubility. Further compounding the 
problem is growing demand for high dose molecules, particularly in the therapeutic area of 
oncology. (9) These high dose systems require high drug loadings in the delivery vehicle in order 
to achieve acceptable pill burden. (10) 
 
A common conceptual approach for solubility enhancement is the use of a spring-parachute 
model wherein the drug is rapidly released into solution in a supersaturated state above its 
equilibrium solubility and then maintained in this state for as long as possible. (11, 12) A 
schematic diagram for this is depicted in Figure 1.1. To meet this model, there are crystalline 
approaches, non-polymeric approaches, and amorphous solid dispersion approaches. Crystalline 
 3 
approaches include: salts, polymorphs, particle size reduction (13), nano-crystal formation (10, 
14), salts and co-crystals (15, 16). However, these processes only impact the spring portion of 
the model and poorly soluble drugs will have a strong tendency to rapidly precipitate and thus 
limiting exposure in patients. Non-polymeric approaches include: lipids (17), cyclodextrins (2), 
and self-emulsifying systems (18). However, these dosages are either limited by carrier solubility 




Figure 1.1: Concept Diagram for Spring-Parachute Approach to Solubility Enhancement. 
Reprinted with permission from (10). 
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Amorphous solid dispersions (ASDs) have greatly increased in importance due to the 
physiochemical properties becoming more challenging and increasing doses limiting the 
applicability of more traditional routes of solubility enhancement. In the ASD approach, drug is 
converted to an amorphous state and, ideally, molecularly dispersed in a pharmaceutical 
polymer. The amorphous form puts the drug in a higher energy state in which dissolution and 
solubility are more favored. The polymer acts to stabilize the drug in the thermodynamically 
unfavorable amorphous state as well as to provide in-solution stability through drug-polymer 
interactions. (20, 21) As Miller et al. notes, this amorphous approach does not come at the 
expense of drug permeability as with other solubility enhancement approaches, i.e., lipid-based 
systems. (22) Spray-drying (23-25) and hot-melt extrusion (26, 27) are common methods of 
producing amorphous solid dispersions; however, these approaches are not without their own 
limitations. Spray-drying is limited by the organic solubility of the drug substance or polymer 
carrier in common organic solvents. If the API is organic solubility limited, then spray-drying 
cannot be used for that molecule as seen with the case study vemurafenib described in detail later 
in this manuscript. (25, 28) As the size and lipophilicity of drug substances continues to increase, 
inadequate organic solubility will be an increasingly common barrier. The formulation space is 
also narrowed by poor organic solubility of some polymers/pharmaceutical additives or by too 
viscous of feed solutions for atomization with other polymer options (e.g. high molecular weight 
hydroxypropyl methylcellulose). (29) When hot melt extrusion (HME) was first introduced, it 
was described as a “renaissance” for amorphous solid dispersion technology. Due to economic, 
environmental, and safety considerations, thermal processes like hot melt extrusion are preferred 
over solvent based processing like spray drying. (30) However, it has since been realized that the 
process can be challenging for high melting point APIs, thermally labile materials, and viscous 
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polymers. (31) As a result, solvent processing is commonly employed due to the described 
limitations of the hot melt extrusion process. With the increasing presence of molecules needing 
enabled formulations such as amorphous solid dispersions, it is of importance to have a toolbox 
of techniques to provide enablement. It is also imperative for these challenging molecules that 
the formulation space be maximized with the widest range of parachutes available. 
 
To address the growing number of challenging compounds in development and their 
formulations, a novel technology, KinetiSol, was developed for production of amorphous solid 
dispersions. KinetiSol utilizes a fusion-based approach to produce amorphous material by 
rotation of a set of protruding blades to apply friction and shear to the material being processed 
at an order of magnitude higher than realized by hot melt extrusion. These non-heat energy 
inputs enable the components to be rendered amorphous at temperatures often well below the 
melting point of the compound and at fast solubilization rates. (32) KinetiSol has also been 
applied to materials that are typically difficult to process into an amorphous solid dispersion, 
including: high melting point APIs, thermally labile components, viscous polymers, and 
materials with poor organic solvent solubility. Subsequent sections will examine multiple of 
these case studies. Figure 1.2 illustrates conceptual diagrams for how the formulation space has 
been expanded by KinetiSol as it relates to the conventionally used hot melt extrusion and spray 
drying processes. Additionally, the initial KinetiSol research was conducted on industry-scale 
plastics equipment to assess feasibility of the process. The technology had to be scaled down for 
pharmaceutical applications which is the opposite of most pharmaceutical technologies. (33) In 
the plastics space, it has already been proven to be viable for large-scale manufacturing and was 
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Figure 1.2: Conceptual Diagrams of the Expanded Formulation Space as it Pertains to the 
Following Process Comparisons: a. KinetiSol and Spray Drying and b. KinetiSol 










1.3.1.1 APIs Used in KinetiSol Processing: 
 
KinetiSol can be applied to compounds requiring an amorphous solid dispersion, even 
compounds that would traditionally be a challenge due to high melting point, organic solvent 
solubility, or thermal instability. As noted in Figure 1.2, it provides unique value to those that 
cannot be melt extruded due to melting point or thermal instability or those without organic 
solvent compatibility. Figure 1.3 shows a conceptual matrix for the applicability of spray drying, 
hot melt extrusion, and KinetiSol as it pertains to API properties of melting point and organic 
solubility. Further discussion of processing challenging APIs will be covered in case studies later 
in the manuscript. A summary of APIs used in KinetiSol processing along with their melting 
points is provided in Table 1.1. It should be noted that the process is not limited to this list as 





Figure 1.3: Conceptual Matrix for Applicability of Amorphous Solid Dispersion Technologies in 




Active Melting Point (°C) KinetiSol Example(s) 
Acetaminophen 169 (117) (33) 
AKBA 295 (77) (37, 77) 
Carbamazepine 190 (118) (38, 46) 
Deferasirox 263 (119) (62) 
Griseofulvin 217 (120) (43, 89) 
Hydrocortisone 220 (121) (43, 44) 
Indomethacin 162 (122) (33) 
Itraconazole 170 (84) (34, 38, 43, 50, 84, 88, 102, 103) 
Ketoconazole 146 (123) (33) 
Meloxicam 270 (64) (64) 
Nifedipine 171 (47) (47) 
Ritonavir 120 (56) (37, 56) 
ROA 230 (45) (45) 
Tetrabenazine 126 (124) (39) 
Vemurafenib 272 (72) (76) 





1.3.1.2 Polymers Used in KinetiSol Processing: 
 
KinetiSol can be used with all polymers commonly used in amorphous solid dispersions. Like 
with APIs, it expands the formulation space for spray drying and hot melt extrusion (as depicted 
in Figures 1.2 and 1.3) to include thermally labile, viscous, and organic solvent insoluble 
polymers. The spray drying process requires a mutual solvent for the API and polymer which can 
be a limiting factor on the formulation space. Additionally, some polymers, such as high 
viscosity hypromellose, are not amenable to the process as the feed solution becomes too viscous 
to form droplets. (29) To thermally process a viscous polymer by hot melt extrusion, the 
inclusion of a stability compromising processing aid is necessary. (31) The KinetiSol process has 
been shown to achieve amorphous solid dispersions with these polymers without this inclusion. 
(34) Additional discussion of processing challenging polymeric carriers will be discussed in a 
later applications section. A summary of polymers that have been used in KinetiSol processing is 



































320,000 111 N/A 176 (33, 43, 45, 50, 77) 







































N/A 200 (33, 34, 39, 88, 89) 
E4M 
(88, 126) 
323,200 180 N/A 200 (88) 




















10,000-500,000 120 N/A 258-276 




10,000-500,000 120 N/A 258-276 (37, 47, 77, 84) 
HF 
(128) 




45,000-70,000 105 N/A 270 (39, 43, 44, 56, 76) 


















4-88 (99) 31,000 40-80 180-240 180 (56, 102, 103) 
5-88 (99) 37,000 40-80 180-240 180 (103) 
8-88 (99) 67,000 40-80 180-240 180 (103) 
18-88 (99) 130,000 40-80 180-240 180 (103) 
4-38 (99) Not available 40-80 180-240 180 (102) 
4-75 (99) Not available 40-80 180-240 180 (102) 
4-98 (99) 27,000 40-80 180-240 180 (102) 


















7,000-11,000 140 N/A 217 (89) 
K30 
(31) 









90,000-140,000 72 N/A 278 (46, 64, 77) 
Table 1.2, cont. 
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1.3.1.3 Additives Used in KinetiSol Processing: 
 
Several classes of pharmaceutical additives are important for amorphous solid dispersions and 
have been used in the KinetiSol process. These additives include: 
• Surfactants – are well understood for their use in amorphous solid dispersions. They have 
a beneficial synergistic effect on drug concentration with polymers through promotion of 
micelles and colloids to prevent crystallization in solution. (35, 36) Docusate sodium is 
one such example explored by KinetiSol. (37) 
• Release modifiers – these agents can be included to create particles or a monolithic 
dosage form in which water ingress is hindered and drug release is slowed. An example 
of this application is glyceryl behenate. (38) 
• Chemical stabilizers – these include functional categories like anti-oxidants, pH 
modifiers, and free radical scavengers. The case study for tetrabenazine includes multiple 
applications in this role. (39) 
• Lubricants – these act as processing aids and improve KinetiSol product discharge 
(yield). One such example is sodium stearyl fumarate (39), although others like 
magnesium stearate have been explored by the authors as well. 
• Moisture scavengers – as their name implies, these absorb and bind water in the dosage 
form and improve storage stability. (40, 41) This is seen in the amorphous dispersion of a 
Norvir®, an approved product for ritonavir. (42) 
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1.3.2 KinetiSol Processing and Equipment: 
 
1.3.2.1 KinetiSol Processing 
 
KinetiSol processing occurs in a cylindrical chamber with a horizontally aligned shaft. A 
simplified schematic diagram of the chamber is shown in Figure 1.4. The shaft has a set of 
protruding blades that undergo controlled rotation to initiate processing of pharmaceutical 
material. On the outer surface of the chamber, a probe is mounted that monitors the temperature 
of the pharmaceutical material in real time with rapid process feedback. Doors are engineered 
into the bottom of the chamber which are designed to rapidly open to allow for quick material 
discharge with the sample being carried out by centrifugal force imparted by the process. 





Figure 1.4: Simplified Schematic Diagram for a KinetiSol Compounder 
 
In the typical KinetiSol process, the workflow progresses through: 
1. Charging the material – the formulation blend is loaded into the chamber which is then 
plugged to seal the machine. 
2. Control parameters – these are input to the unit to dictate the execution of the process. 
These parameters are described in detail below. 
3. Process initiation - the operator triggers the process and rotation of the blades commences 
automatically. 
4. Discharge – the doors of the unit rapidly open and material is ejected. 
5. Quenching – the molten mass can be quenched in a variety of ways, most involving 
pressing the material to a flat disk to maximize the surface area and heat transfer out of the 
sample. Manual quenching can be performed by an operator transferring the molten mass to the 
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surface between two metal plates with pressures applied by the operator or a pneumatic press. 
Automatic quenching can also be used to quench the sample as it ejects from the unit. 
6. Milling – the quenched sample is milled to reduce sample particle size to the desired 
outcome. 
 
For operation in batch mode, steps 1, 2, 3, and 5 are manually executed by an equipment 
operator for each aliquot of material. In semi-continuous mode, blended material is loaded into a 
feed system and parameters are input to the system. The unit runs a described number of batches 
consecutively operating steps 1-5 autonomously. This mode of operation allows large quantities 
of materials to be processed without intervention from technicians. 
 
The KinetiSol process has several control parameters that are adjusted to achieve desired 
processing outcomes: 
• Rpm controls the rotational speed of the blades in the chamber. Lower rotational speeds 
may be beneficial for samples that are shear sensitive, are low viscosity, or need longer 
processing times to be rendered amorphous. Higher rotational speeds benefit systems that 
include viscous polymers, require more frictional energy input to become molten, or need higher 
shear rates. 
• Temperature provides feedback on the state of the material in the chamber. Temperature 
change is influenced by the rpm of the process and can rise rapidly to the desired ejection 
temperature. As a processing parameter, when the pre-set temperature is reached the sample is 
ejected. 
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• Time can be used to control how long the process occurs. This can be useful for 
maintaining mixing conditions or controlling the duration of time that a sample is exposed to 
aggressive conditions. (33) 
 
The temperature of the chamber is plotted against run time to create a processing profile for the 
batch. Figure 1.5 shows processing profiles from an example DOE in which rpm and ejection 
temperature parameters were modified from run to run. As shown in these processing profiles, 
rpm influences the duration of both the overall process and the time before temperature increase 
occurs as well as the rate of temperature increase. Higher rpms promote shorter processing times 





Figure 1.5: Sample KinetiSol Profiles. Reprinted with permission from (56). 
 
1.3.2.2 KinetiSol Equipment 
 
KinetiSol Research Formulator, KBC20: 
 
As the smallest size unit, the KinetiSol Research Formulator was designed with formulation 
screening and feasibility assessment in mind. Batch size in the Formulator ranges from 7 to 15g 
which minimizes the use of material when compared to other units for KinetiSol processing. The 
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entire chamber and blades are easily replaceable allowing for chambers to be swapped in from 
batch to batch to improve throughput. This enables rapid processing of formulations without the 
need to clean equipment between each composition. Feed and quenching operations are 
conducted manually, but the process is monitored and executed in real time by a computer 
monitoring system. Processing time for each batch is typically between 5 and 20 seconds. The 
system is dimensionally smaller than other KinetiSol units as seen in the image of a Formulator 
shown in Figure 1.6. 
 
 




KinetiSol Batch Compounder, KBC250: 
 
At the time of this writing, most of the published research and patents with KinetiSol was 
conducted on a Batch Compounder unit. The batch size in the Batch Compounder ranges from 
50 to 350g. The unit can be used to facilitate preclinical and early stage clinical supply with up to 
10 kg of manufactured material being reasonable. Scale-up of processing parameters from the 
Formulator unit principally involves applying a linear scaling factor to the rotational speed, with 
all other parameters remaining the same. Like the Formulator, feed and quenching operations are 
conducted manually with control in real time by a computer monitoring system. Processing time 
is typically between 5 and 20 seconds for each batch. An image of a Batch Compounder is 
shown in Figure 1.7. 
 
 




KinetiSol Continuous Compounder, KCC250: 
 
The KinetiSol Continuous Compounder is designed with large scale manufacturing options in 
mind. The geometry and size of the unit matches that of the Batch Compounder. Thus, process 
development is streamlined when transitioning to high-volume manufacturing because there is 
no scale-up required, just optimization for continuous processing. Batch size is also 50 to 350g 
and processing conditions developed on a Batch Compounder directly translate to the 
Continuous Compounder. However, the unit is equipped with an automated feed and quenching 
system which greatly increases the throughput, up to 40 kg/hr. The unit’s size is 34” x 75” x 60” 
which potentially enables multiple units to be set up in a single processing suite to increase 
throughput further if necessary. The unit has the capability to supply materials for Good 
Manufacturing Practices (GMP) Phase I through commercial manufacturing. As is the case for 
all KinetiSol units, processing time is typically between 5 and 20 seconds for each batch. The 
system is configured so that the next batch begins feeding automatically as soon as the ejection 






Figure 1.8: Photograph of the KinetiSol Continuous Compounder, KCC250 
 




The KinetiSol process can be applied to drug substances and polymers to produce amorphous 
solid dispersions. However, it is unique in its ability to process: high melting point drugs, 
thermally labile APIs and polymers, drugs/polymers with poor organic solubility, and high 
molecular weight viscous polymers. These applications represent an expansion of the 
formulation space over conventional hot melt extrusion and spray drying approaches. Each of 
these unique capabilities will be explored in the subsequent sections. 
 
The KinetiSol process has been utilized to generate amorphous solid dispersions for many active 
pharmaceutical ingredients. When the process was first applied to pharmaceutical compositions, 
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feasibility was immediately established for a number of active pharmaceutical ingredients 
including: acetaminophen, griseofulvin, hydrocortisone, itraconazole, indomethacin, and 
ketoconazole. (33, 43) After the initial assessment, additional studies were performed to compare 
the novel process of KinetiSol to the more established thermal process of hot melt extrusion. (44, 
45) In addition to the traditional processing polymers explored in these studies, other options 
such as Soluplus® (46) and low-substituted hydroxypropylcellulose (L-HPC) (47) were also 
found to be amenable to the KinetiSol process. Other studies have shown the process is agreeable 
to the inclusion of additives, e.g. anti-oxidants for degradation protection, to provide additional 
functionality to the produced amorphous solid dispersions. (39) 
 
Subsequent sections will focus on compositions that present unique challenges for processing 
into amorphous solid dispersions. 
 
1.4.1 API Challenges 
 
1.4.1.1 Thermally Labile APIs 
 
Thermally labile active pharmaceutical ingredients are susceptible to drug substance degradation 
during processing by thermal techniques. Common strategies to reduce thermal degradation 
include: lowering of processing temperatures (often through inclusion of plasticizers), shortening 
processing times, and inclusion of additives to inhibit the mechanism of degradation. KinetiSol 
has the innate advantage of processing at lower temperatures and for residence times in the range 
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of seconds rather than minutes which gives it a unique advantage over other thermal processing 
techniques. (26, 31, 48-51) Figure 1.9 shows an overlay of a KinetiSol profile with a HME 
profile for a similar composition. It is apparent from this figure that the amount of total thermal 
exposure of a KinetiSol sample is significantly less than that required by the HME process. As 
exposure to thermal conditions increases, the risk of API degradation increases and the process 
becomes less viable. Some examples of thermally labile APIs processed by KinetiSol follow. 
 
 
Figure 1.9: Comparison of Temperature Vs. Time Plots Depicting Total Thermal Exposure of an 
Itraconazole-HPMC E5 System when Processed by Both Hot Melt Extrusion and 
KinetiSol. KinetiSol plot adapted from (34). Hot melt extrusion plot approximated 

























In patent application WO/2015/175505 filed by Miller et al., thermally labile tetrabenazine was 
processed by KinetiSol. Tetrabenazine is used for treatment of chorea in patients with 
Huntington's disease and is available as Xenazine®, the only FDA approved product for this 
treatment. Xenazine is an immediate release product of the weakly basic tetrabenazine in which 
patients are exposed to an initially high amount of tetrabenazine due to extensive gastric 
solubility, rapid and complete absorption, and then swift elimination. A significant challenge is 
that dosing of tetrabenazine is limited by the onset of side effects which correlate to Cmax, and 
patients are individually dose titrated until onset occurs. For many patients, this results in a 
lowering of dose and an overall reduction in efficacy. Thus, there is a demonstrated need for 
improved formulation with modified release properties to produce higher drug solubility in pH 
neutral environments and blunted Cmax, but with similar AUC in respect to Xenazine. 
A new, modified release formulation for tetrabenazine was pursued using the KinetiSol process. 
Several compositions were explored including various grades of HPMC and in some instances 
copovidone was included as a secondary polymer. It became apparent during development that 
oxidative thermal degradation was a challenge that needed to be overcome. Both formulation and 
process approaches were employed to overcome this barrier. For formulation approaches, 
combinations of butylated hydroxytoluene, butylated hydroxyanisole, and sodium ascorbate were 
added to the amorphous solid dispersion as antioxidants to counteract this route of degradation. 
From a process approach, the compounder chamber was purged with dry nitrogen gas prior to 
processing. This step reduced the amount of oxygen available in the process, particularly when 
the sample was at elevated temperatures. The results of the combined formulation and process 
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adjustments resulted in several tetrabenazine amorphous solid dispersions with acceptable 
impurity profiles. 
 
The goals of the tetrabenazine amorphous solid dispersions were to provide controlled release of 
the drug that was less dependent on pH and to reduce Cmax without sacrificing systemic 
exposure. In-vitro and in-vivo analyses were conducted on the KinetiSol samples. As shown in 
Figure 1.10, pH change dissolution studies demonstrated that Xenazine behaved as expected with 
complete immediate release in the acid phase of the test followed by rapid precipitation to the 
equilibrium solubility of tetrabenazine of approximately 30 µg/mL in media with pH greater than 
4. By contrast, the modified release formulations produced by KinetiSol released across a range 
of concentrations during the 2 hours in gastric media, and were followed by equilibrium in-
solution concentrations as high as 50 µg/mL after conversion to neutral media. These four test 
articles demonstrated that tetrabenazine can be formulated to release across a range of 
concentrations in the gastric phase with continued drug release and exposure during intestinal 
transit. Samples were also formulated into tablets and dosed to fasted male beagle dogs and 
multiple articles showed promising data for Cmax reduction with similar AUC to Xenazine and 
were selected for dosing in healthy fasted human volunteers. Table 1.3 summarizes these healthy 
volunteer results. Formulations containing HPMC E3, HPMC E5, and HPMC E15/VA64 had 
AUC values that were within 5% of Xenazine, but had Cmax values that were 66%, 55%, and 
45% of Xenazine’s Cmax, respectively. These three formulations show the potential to be 
titrated to higher doses in patients before side effect onset which would allow for increased 




Figure 1.10: Non-Sink Gastric Transfer Dissolution Testing of Tetrabenazine Modified Release 
Formulations and the Approved IR Product, Xenazine.  At pH 1.2, tetrabenazine 
dissolved to a level of 2.4% of its equilibrium solubility, whereas at pH 6.8, 




Formulation Xenazine HPMC E3 HPMC E5 HPMC E50/VA64 HPMC E15/VA64 
tmax (h) 1.25 (36%) 3.04 (24%) 3.79 (22%) 3.58 (34%) 3.71 (34%) 
Cmax (ng/mL) 51.56 (64%) 34.20 (56%) 28.40 (37%) 20.99 (55%) 23.37 (48%) 
AUC0→∞ 
(hr∙ng/mL) 
248.4 (63%) 240.5 (54%) 252.7 (70%) 201.8 (54%) 238.8 (54%) 
Table 1.3: Human Pharmacokinetic Study Results for Dosing of KinetiSol Modified Release Formulations of Tetrabenazine and the 





Ritonavir (RTV) is a poorly soluble, weakly basic active pharmaceutical ingredient that has been 
processed into a number of commercial products by hot melt extrusion (52, 53) and has seen 
application as a permeability enhancer. (54) Studies have shown that ritonavir is shear sensitive, 
experiencing chemical instability during high shear conditions. (55) A shear sensitive molecule 
presents a unique challenge to KinetiSol compared to hot melt extrusion as the process utilizes 
shear an order of magnitude higher. Preformulation work by LaFountaine et al. found that 
ritonavir was thermally stable up to a temperature of 160°C after which significant chemical 
degradation was observed. Tertiary systems containing polyvinyl alcohol, copovidone, and 
ritonavir were processed by KinetiSol with rotational speeds varying from 1000 to 2000 rpm and 
ejection temperatures from 80°C to 100°C. All but the lowest energy input (1000 rpm and 80°C) 
were found to be amorphous with respect to ritonavir. Degradation was observed to increase with 
increasing energy input with the strongest contribution to degradation coming through shear 
input. This data is depicted in Figure 1.11. However, a number of amorphous compositions were 




Figure 1.11: Ritonavir Impurities as a Function of Rotation Speed and Ejection Temperature. 
Reprinted with permission from (56). 
 
Due to processing limitations, polyvinyl alcohol is a little utilized polymer in amorphous solid 
dispersions and is further explored in the related polymer section below. 
 
A ritonavir amorphous solid dispersion was also explored for use in a combination product with 
acetyl-11-keto-beta-boswellic acid (AKBA). In the commercial product Norvir, an amorphous 
dispersion of ritonavir is included with 15% w/w drug loading in its amorphous phase. (42) For 
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the RTV-AKBA combination product, this drug load was calculated to be inadequate for the 
intended design and a new formulation was required. An amorphous 30:65:5 
RTV:HPMCAS:docusate sodium formulation was developed to increase the drug load. 
Dissolution results of this amorphous solid dispersion are shown in Figure 1.12. While the 
enteric nature of the formulation limited its release in the acid phase, pH change to 6.8 initiated 
rapid drug release with equilibrium solubility essentially equivalent to that of the crushed Norvir 
tablet. Both samples are well above the literature reported value of ritonavir at 1 µg/mL in pH 
6.8 media. The profile was also in sync with the AKBA release profile ensuring similar time and 
location exposure in-vivo. This new formulation matched the drug load and dissolution 
requirements for a fixed-dose combination product with AKBA. (37) The AKBA portion of the 




Figure 1.12: pH Change Dissolution Profiles of KinetiSol Ritonavir Amorphous Intermediate as 




Hydrocortisone is a thermally labile active pharmaceutical ingredient which has been previously 
studied as a component in amorphous films. During these studies, films containing 
hydrocortisone produced by hot-melt extrusion were found to have significant oxidative 
degradation at elevated temperatures. (57) DiNunzio et al. hypothesized that thermal degradation 
was related to cumulative exposure during hot melt extrusion and that processing by the 
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relatively shorter KinetiSol would yield product with significantly reduced degradation. 
Preformulation work conducted using optical hot stage imaging revealed that copovidone 
allowed processing at a temperature of 160°C while HPMC required a processing temperature of 
180°C which posed a higher risk for degradation. These results are depicted in Figure 1.13. Thus, 
copovidone was selected as the carrier for subsequent studies. 
 
 
Figure 1.13: Optical Microscopy Analysis for Miscibility of Hydrocortisone (HTC) with HPMC 
E3 and Copovidone (PVPVA). Reprinted with permission from (44). 
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Compositions of hydrocortisone-copovidone were prepared by both hot melt extrusion and 
KinetiSol. The KinetiSol material had reduced degradation compared to the hot-melt extrusion 
material which the authors ultimately attributed to reduced processing temperature and shorter 
residence times in the process (less than 30 seconds total with temperatures above 130°C for 
under 5 seconds). (44) Thus, it was concluded that for the thermally labile hydrocortisone, 





Another investigation into a thermally labile API was conducted by Hughey et al. on a Roche 
research compound, ROA. Preformulation studies for ROA demonstrated that it was susceptible 
to thermal and acidic degradation at elevated temperatures. Initially, the authors processed ROA 
by hot melt extrusion with Eudragit® L100-55 and HPMCAS as the polymeric carriers. 
However, they found that ROA was processable into an amorphous dispersion containing L100-
55 only with the inclusion of a plasticizer (triethyl citrate) or when ROA was micronized during 
pre-processing. (45) The inclusion of plasticizers in amorphous compositions is known to 
increase the molecular mobility of the system through lowering the glass transition temperature 
of the system. This can ultimately lead to phase separation and recrystallization. (58) It could not 
be rendered fully amorphous at all with HPMCAS. For both compositions by hot melt extrusion, 
unacceptable levels of ROA related impurities were observed. By contrast, when processed by 
KinetiSol, both compositions were generated as substantially amorphous with significantly better 
impurity profiles compared to the hot melt extrusion compositions. Ultimately, amorphous 
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compositions by both methods could produce approximately threefold higher equilibrium 
solubility for ROA in aqueous solution. However, the KinetiSol process could realize these 
solubility gains without sacrificing chemical stability of the drug substance. (45) 
 
1.4.1.2 High Melting Point APIs 
 
Active pharmaceutical ingredients with high melting points represent a challenge to conventional 
methods for thermal processing, like hot melt extrusion. The challenges with processing these 
high melting point molecules through thermal processing (without the inclusion of processing 
aids) has been extensively documented. (31, 51, 59-61) However, a number of examples exist for 
which the high shear process, KinetiSol, can render these actives amorphous at temperatures 
significantly below their melting point and without the inclusion of processing aids. Some of 




An example of a high melting point drug successfully processed by KinetiSol is deferasirox, as 
demonstrated in patent application WO/2016/205658. Deferasirox (DFX) is an orally delivered 
iron chelator used in the treatment of chronic iron overload in patients who are receiving long-
term blood transfusions. It is commercially available in the United States as Exjade® and 
Jadenu®. Deferasirox delivery from these dosage forms is noted as having highly variable 
delivery stemming from issues with the pH dependent solubility of the molecule. As a weak acid, 
deferasirox has poor gastric solubility which can lead to drug aggregate formation limiting 
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intestinal absorption. (62) Deferasirox is also a high dose therapy (up to 40mg/kg/day) and when 
coupled with solubility challenges leads to ~30% of patients absorbing the drug poorly and not 
responding to treatment. This unmet need of improving bioavailability for these non-responder 
patients is where an improved formulation would have significant value. (63) It was 
hypothesized that an amorphous solid dispersion of deferasirox would hinder drug aggregate 
formation and improve bioavailability. However, processing deferasirox by hot melt extrusion 
would represent a significant challenge as deferasirox’s melting point of 264-265°C would 
require processing temperature that would degrade the polymers employed. Spray drying 
deferasirox is challenging as it has limited solubility in organic solvents commonly used in the 
spray drying process. 
 
The KinetiSol process was deployed to generate amorphous solid dispersions of deferasirox. 
Systems containing deferasirox and one or more of copovidone, HPMCAS, and Eudragit were 
manufactured with deferasirox drug loads of 40-60%, except in the case of binary 
deferasirox/HPMCAS where maximal drug load was 20%. These systems were found to be fully 
amorphous by x-ray powder diffraction and maintained a lack of crystallinity for 2 months of 
storage at 40°C/75% R.H. in an open container. Modulated differential scanning calorimetry 
showed all systems as single phase with sufficiently high Tgs to suggest samples would be stable 
at typical storage conditions. High performance liquid chromatography analysis for purity 
showed that all samples were >99.9% pure with respect to deferasirox except for the binary 
deferasirox/Eudragit system which had a purity of 99.5%. These high levels of purity were 
possible due to the short processing time (<10 seconds at elevated temperature) and low ejection 
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temperature (170°C, approximately 90°C below melting temperature) which would have been 
challenging to replicate by hot melt extrusion. 
 
The amorphous intermediates, neat API, and Jadenu were tested for in-vitro performance by pH 
change dissolution from pH 1.1 to pH 6.8. The results are shown in Figure 1.14. None of the 
tested dosage forms had any detectable release of deferasirox during the acid phase of the test. 
After the pH change, neat API, Exjade and Jadenu surprisingly showed release only up to 25% of 
the theoretical load of deferasirox. By contrast, drug from the amorphous dosage forms released 
to approximately 80% of theoretical drug load demonstrating a clear advantage of amorphous 
delivery of deferasirox over its crystalline form. Using the amorphous dispersions, a range of 
tablets were made that had properties that varied from disintegrated to eroding performance. 





Figure 1.14: pH Change Dissolution Testing of Deferasirox Amorphous Solid Dispersion 
Intermediates Produced by KinetiSol as Compared to the FDA Approved Jadenu 
and Neat API. Reprinted from (62). 
 
For initial in-vivo testing, two tablet formulations were dosed at 36 mg/kg in a fasted dog model 
against Exjade and Jadenu. The plasma concentration profile for DFX is shown in Figure 1.15 
and both formulations exhibited >300% increase in deferasirox exposure. Following the dog 
study, two formulations were dosed in a crossover study in healthy human volunteers under 
fasted conditions. The results of this PK study are summarized in Table 1.4. Both formulations 
exhibited approximately 30% higher Cmax, 17% higher AUC, and reduced variability relative to 
Jadenu. Notably, while many test subjects had similar exposure to both Jadenu and the KinetiSol 
formulations, multiple patients exhibited a substantial reduction of Jadenu exposure compared to 
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the KinetiSol dosage. These results may represent a response in a non-responder population. 
Thus, it was demonstrated that an amorphous solid dispersion of deferasirox processed by 
KinetiSol could be utilized for superior delivery and clinical efficacy. (62) 
 
 
Figure 1.15: Deferasirox Blood Plasma Concentrations in Fasted Beagle Dogs of KinetiSol 






Formulation 30011 Formulation 30012 Reference (Jadenu) 
Mean (C.V. %) Mean (C.V. %) Mean (C.V. %) 
Cmax (ng/mL) 55.636 (25.4) 58.019 (27.2) 45.071 (38.8) 









590.016 (31.9) 556.538 (31.8) 542.527 (46.4) 
Table 1.4: Pharmacokinetic Evaluation in a Crossover Study in Healthy Human Subjects 
Comparing Two KinetiSol Formulations to the Reference Product Jadenu Dosed at 




Meloxicam is a high melting point molecule (270°C) (64) for which there is an interest to form 
solid dispersions to aid in solubility enhancement. (65-69) After preformulation work to screen 
for a carrier that promoted solubility in aqueous media and had good miscibility for processing, 
Hughey et al. moved forward with development of a 10% meloxicam amorphous solid dispersion 
with Soluplus. As part of the development, the authors also processed and compared the 
formulations by hot melt extrusion. It was found that hot melt extrusion could not render the high 
melting point drug substance into an amorphous composition even with recirculation for 2 
minutes at 175°C. The purity of the drug substance at these conditions was 87% which indicated 
substantial degradation of meloxicam. (64) In a separate hot melt extrusion study, a binary 
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amorphous solid dispersion was produced with 10% meloxicam in copovidone. Through 
rigorous process optimization and extruder design, purity was reduced as far as possible 
(recovery 96.7%), but it was not until the addition of the base meglumine to chemically stabilize 
meloxicam that an acceptable purity level was reached. (70) However, additives can negatively 
impact the physical stability of amorphous solid dispersions and meglumine has been shown to 
act as a destabilizer in some systems. (71) By contrast, amorphous compositions could be 
processed by KinetiSol with substantially less degradation. Compositions were processed as low 
as 110°C with a total processing time of less than 25 seconds. For KinetiSol, the strongest 
correlation between processing conditions and degradation was ejection temperature with all 
compositions at 110°C having 98% or greater purity. While the key study parameters (rpm and 
ejection temperature) were probed for their impacts, the process was not fully optimized and it is 
likely that with additional experimentation that the impurities could be reduced to negligible 
levels. (64) This case study demonstrated the capability of KinetiSol to produce an amorphous 
dispersion of a high melting point compound when the more limited processing space of hot melt 




Vemurafenib is BCS Class II/IV drug for which a clear need for an amorphous form exists as it 
has <2 μg/mL solubility in aqueous vehicles. However, as noted by Shah et al., its high melting 
point of 272°C and poor organic solubility of <6 mg/mL in solvents amenable to spray drying 
make it a challenging entity for processing into an amorphous dispersion by conventional means 
(e.g., hot melt extrusion and spray drying). (72) In the case of hot melt extrusion, the highest 
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reported drug loading achieved with vemurafenib was 10% w/w in a binary copovidone 
amorphous solid dispersion. Drug load could be increased as high as 20-25% with the inclusion 
of 5-15% glyceryl monostearate, a plasticizer. (73) Additionally, clinical trial results dictated a 
dosing of 960 mg (4 x 240 mg tablets) of amorphous vemurafenib twice-daily in patients. (74) 
This high dose requirement limits the application of hot melt extrusion and created a driver for 
an approach that could yield an amorphous solid dispersion with higher drug load. 
 
A novel process of solvent-controlled coprecipitation was developed in which an amorphous 
solid dispersion of 30/70 vemurafenib/HPMCAS-LF was precipitated in an anti-solvent 
(acidified aqueous media) from dimethylacetamide. (72) However, this process has a number of 
limitations including: the requirement of ionic polymers, difficulty in developing suitable 
solvent/anti-solvent systems, inability to include solubility/permeability enhancers in the 
dispersion, and stability risks due to matrix exposure to water during preparation. (75) In the case 
of Zelboraf® (vemurafenib) development, the formulation space was limited to HPMCAS, 
Eudragit, and hypromellose phthalate. (72) It is plausible that an optimized formulation with 
improved bioavailability and lower dosing exists outside of this narrow domain. 
 
Despite the difficulties with processing vemurafenib by other amorphous solid dispersion 
approaches, several amorphous compositions of vemurafenib have been made utilizing 
KinetiSol, as described in WO/2016/073421. An equivalent composition to the solvent-
controlled coprecipitation process was developed. The composition was found to be amorphous 
by X-ray powder diffraction and with a similar Tg by modulated differential scanning 
calorimetry. Dissolution performance testing mimicking the work described by Shah et al. 
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showed similar performance between the precipitated and KinetiSol produced materials. 
Additional compositions were prepared utilizing HPMC E5 and PVP VA64 as carrier polymers 
with additional batches produced with docusate sodium as an internal component in the 
amorphous dispersion. These batches were shown to be amorphous and demonstrated the 
capacity for KinetiSol to produce additional formulations not achievable by other means, 
whether it be conventional or the novel solvent-controlled coprecipitation process. (76) The 
expanded formulation space enabled by KinetiSol presents the possibility of an improved 




3-acetyl-11-keto-beta-boswellic acid (AKBA) is a poorly aqueous soluble (77), high melting 
point (295°C) compound with increasing interest. (78) Historically, all of the boswellic acids 
have been known to have anti-inflammatory properties (79) while more recently AKBA has 
gained attraction for its promising anti-tumor properties. (80) To better deliver AKBA, Bennett 
et al. explored amorphous solid dispersions for solubility enhancement of this molecule. During 
thermal preformulation evaluations, the authors identified that the processing conditions required 
to thermally process AKBA by hot melt extrusion would pose significant risk to polymer and 
drug degradation. In moving forward, Bennett et al. processed amorphous compositions 
containing AKBA with various polymeric carriers: HMPCAS-LF, HPMCAS-MF, Eudragit 
L100-55, and Soluplus. Additionally, all compositions were prepared with docusate sodium in 
the amorphous dispersion to act as a surfactant for further improvement of aqueous solubility. 
For all compositions, the resulting material was substantially amorphous and possessed 
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acceptable recovery of the drug substance which validated the feasibility of KinetiSol to process 
compositions of AKBA. As a comparator, equivalent compositions were produced by rotary 
evaporation. In-vitro dissolution studies demonstrated that both processing methods significantly 
enhanced solubility of AKBA. However, the authors also identified that for some compositions 
there were surface morphology differences that resulted in a performance difference of the rotary 
evaporated material compared to material produced by KinetiSol. These results carried over to an 
in-vivo rat study in which oral absorption was seen at levels approximately 18-fold higher than 
crystalline AKBA. (77) 
 
However, recent literature has shown that permeability of AKBA is also a significant limitation 
in its delivery. (81) Specifically, Kruger et al. demonstrated that metabolic enzymes in the 
intestinal tract led to extensive metabolism of the compound. (82) Miller et al. hypothesized that 
inhibition of these metabolic enzymes could be utilized to enhance the permeability of AKBA, 
further boosting its oral bioavailability. (37) Ritonavir was known to be an effective CYP3A 
enzyme inhibitor as evidenced by its success with Kaletra, a combination product which included 
amorphous ritonavir to boost the permeability of the highly metabolized lopinavir. (53) To this 
end, Miller et al. (37) processed amorphous compositions of AKBA like the work performed by 
Bennett et al. (77) as well as separate amorphous dispersions for ritonavir by KinetiSol. Tablets 
were made of the blended amorphous dispersions and dosed in an in-vivo dog study. The 
combination of enhanced solubility from amorphous AKBA as well as the enzyme inhibition 
from ritonavir yielded oral absorption approximately 4 times the AKBA composition alone and 
24 times the crystalline drug. See Figure 1.16 for the plasma concentration profiles. These results 
demonstrated the utility of KinetiSol processing to enhance oral absorption of the challenging 
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AKBA molecule through both solubility enhancement by amorphous dispersion and delivery of a 
solubility challenged enzyme inhibitor. (37) 
 
 
Figure 1.16: Plasma Concentrations of AKBA-RTV Tablets Against Pure AKBA in a Fasted In-




1.4.2 Polymeric Excipient Challenges 
 
1.4.2.1 High Molecular Weight, Viscous Polymers 
 
High molecular weight polymers have been demonstrated to be challenging to process by 
thermal methods such as hot melt extrusion. (31, 51, 59-61) However, these polymers are 
desirable for use in amorphous solid dispersions as a number of studies have demonstrated the 
benefit of increased molecular weight and solubility gains. (34) This benefit has been attributed 
to inhibition of precipitation through drug-polymer interactions, steric hindrance of the active 
pharmaceutical ingredient, and improved shielding from dissolution/recrystallization during the 
gelling process. (83-85) Many studies have been performed utilizing KinetiSol to process 
amorphous solid dispersions with high molecular weight polymers to enhance drug release and 
oral absorption. These are discussed below. 
 
Feasibility of Processing HPMC E50 by Thermal Processing Methods: 
 
Hughey et al. conducted a series of experiments to compare the feasibility of processing 
compositions containing high molecular weight HPMC E50 by hot melt extrusion and KinetiSol. 
Compositions of 1:2 itraconazole:HPMC E50 were attempted by hot melt extrusion using a 
Minilab II extruder. Processing temperature was maintained at 180°C with screw rotation at 150 
rpm without recirculation. This processing temperature was found to be necessary as lower 
temperatures resulted in torque loads that exceeded the capacity of the instrument. At this 
processing temperature, significant browning of the material was observed with subsequent 
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analysis determining that there was an 18.4% loss in molecular weight of the polymer. 
Additionally, to assess the presence of metals in the dispersion caused by strain on the extruder, 
metals analysis of the composition was conducted and the HME composition was found to have 
450 ppm of iron with detectable levels of chromium, nickel, copper, and zinc present as well. 
Between the significant degradation of the polymer and the presence of metals in the dispersion 
indicated a lack of feasibility for hot melt extrusion to process the desired composition. (34) 
 
Subsequently, Hughey et al. processed the same composition by KinetiSol at 1750 and 2250 rpm 
and ejections temperatures of 120 and 180°C. Degradation of the polymer was also observed in 
these samples with statistical correlations to both ejection temperature and rotational speed. 
However, size exclusion analysis showed a reduction of 12.8% in molecular weight, an 
improvement on the best-case result obtained from hot melt extrusion. Metals analysis was also 
conducted on the KinetiSol material. Iron was found a level of 21 ppm, significantly less than the 
hot melt extrusion result, with none of the other metals detected in the composition. (34) These 
results indicated the challenge in processing high molecular weight HPMC E50 by hot melt 
extrusion and the potential feasibility of KinetiSol in this area. 
 
HPMC E50 and E4M Delivery of Itraconazole: 
 
Itraconazole is a poorly soluble BCS class II drug used in the commercial Onmel® product as an 
antifungal agent. In this product, itraconazole is delivered orally as a tablet containing an 
amorphous solid dispersion of the drug with HPMC E5. (86) Given the potential of higher 
molecular weight polymers to further enhance solubility (87), Keen et al. hypothesized that an 
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amorphous solid dispersion of itraconazole in HPMC E50 or E4M could provide equivalent or 
better oral absorption than Onmel without conflicting with the product patent. As shown in the 
previous section, HPMC E50 was not processable with itraconazole by hot melt extrusion. The 
authors utilized KinetiSol to process amorphous solid dispersions of itraconazole. The 
amorphous dispersions were milled and a series of tablet dispersions were developed which 
yielded tablets that were non-disintegrating and resulted in viscous gel formation. In-vitro 
analysis showed a significant reduction in drug dissolved in acid compared to Onmel, despite 
itraconazole’s affinity for dissolution in acidic media. This was attributed to the controlled 
release nature of the viscous gel formed by the higher molecular weight HPMC. In a number of 
examples, tablets from the higher molecular weight dispersions resulted in supersaturation 
maintenance well into neutral phase whereas the Onmel product approached no drug in solution 




Figure 1.17: In-vitro Testing of High Molecular Weight HPMC Compositions Containing 
Itraconazole. Reproduced from (88). 
 
Two lead candidates (one of each polymer type) were selected based on small volume 
dissolution performance for study in an in-vivo dog model. In this model, the E4M dispersion 
performed similarly to the Onmel product. The E50 controlled release tablet appeared to 
outperform the comparator product, but the sample size was too small to obtain statistically 
significant results. The plasma concentration profiles are reproduced in Figure 1.18. (88) 
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However, these results demonstrate the utility of KinetiSol to produce alternative formulations 
that may have more desirable properties such as controlled release or superior supersaturation. 
 
 
Figure 1.18: In-Vivo Performance in Dog Model of High Molecular Weight HPMC 
Compositions Containing Amorphous Itraconazole. Reproduced from (88). 
 
Processing Evaluation for Various Grades of PVP and HPMC: 
 
In another study, LaFountaine et al. examined the capability of hot melt extrusion and KinetiSol 
to process compositions containing various grades of povidone (K17, K30, and K90) and HPMC 
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(E5, E15, and E50) with a model compound, griseofulvin, at various drug loads (10-40%). Due 
to processing challenges, namely high torque and high pressure, only K17 and HPMC E5 were 
processable but hot melt extrusion. By contrast, all compositions could be processed by 
KinetiSol into amorphous solid dispersions except for K30 at 40% drug load. Also, for K17 and 
HPMC E5, hot melt extrusion could only process amorphous compositions at drug loads of 10 
and 20% while KinetiSol could process compositions up to 40% drug load. The authors cited the 
high shear output of KinetiSol as the most likely explanation for its ability to process these 
challenging compositions. (89) 
 
1.4.2.2 Thermally Labile Polymers 
 
Like thermally labile active pharmaceutical ingredients, carrier polymers are often susceptible to 
degradation during thermal processing. (59-61, 90) Similar strategies exist for minimizing this 
degradation through lowering the processing temperature, inclusion of plasticizers, and 
shortening processing times. The same advantages that KinetiSol has for processing thermally 
labile APIs (lower processing temperatures and shorter processing times as seen in Figure 1.9) 
apply to thermally sensitive polymers as well. (31, 51) A number of examples have already been 







HPMCAS is a hydroxypropylmethylcellulose based polymer with substitution of acetyl and 
succinoyl groups. Three grades are primarily available and are described in Table 1.5. Depending 
on the degree of substitution of acetyl and succinoyl, the pH solubility profile of the polymer is 
impacted and the polymers exhibit various degrees of enteric release. (91) These functional 
groups, predominantly acetyl, have been shown to promote improved drug solubility through 
hydrophobic interactions with the drug preventing recrystallization. (21) 
 
Grade % Acetyl Substitution % Succinoyl Substitution pH 
L 7 16 >5.5 
M 9 12 >6.0 
H 12 6 >6.8 
Table 1.5: Acetyl and Succinoyl Substitutions of HPMCAS and Resulting pH of Dissolution of 
Polymer. Data summarized from (91). 
 
When processing amorphous solid dispersions with HPMCAS, it is important to not change the 
functional group substitutions to maintain desired pH and recrystallization inhibition properties. 
A study was conducted with the three primary grades of HPMCAS used in hot melt extrusion at 
various temperature and rpm conditions. As a result of processing, all three grades showed an 
increase in free acetic and succinic acid which was indicative of degradation of the acetyl and 
succinoyl groups. The H grade, in particular, showed significantly increased dissolution time 
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after processing which would concurrently limit drug release in an amorphous solid dispersion 
system. (91) Review conducted by LaFountaine et al. found that HPMCAS possesses no suitable 
extrudable range as it requires temperatures above 170°C to sufficiently reduce its melt viscosity 
but degradation onset occurs as low 180°C. (31) This limitation of HPMCAS presents a 
challenge when processing high melting point drugs like telaprevir (246°C) (92), ivacaftor 
(292°C) (93), and vemurafenib (272°C) (72) in hot melt extrusion. Alternative processes were 
pursued to make commercial products with spray drying used to make Incivek® (telaprevir) and 
Kalydeco® (ivacaftor) (28) and solvent controlled coprecipitation to make Zelboraf 
(vemurafenib). (72) 
 
Like its success with viscous, high molecular weight polymers, KinetiSol has been used to 
process amorphous solid dispersions containing HPMCAS. In the vemurafenib example 
previously described, the sample containing 70% HMPCAS-L was ejected at 180°C after 
approximately 7 seconds of processing time. While the polymer reached the reported degradation 
onset during processing, the process ejected sample as it reached this level and the overall 
processing time was minimal which limited degradation. (76) In the previously described 
ritonavir example, both the HPMCAS polymer and the drug substance are susceptible to thermal 
degradation. However, the process only required a final temperature of 90°C to render the 
sample fully amorphous. This value was substantially below the degradation onsets for both the 
drug and HPMCAS. The study demonstrated a case where KinetiSol enabled the processing of a 
composition approximately 80°C below the polymeric carrier’s minimum operating temperature. 
This occurred as a result of KinetiSol high shear reducing the melt viscosity of HPMCAS 





Eudragit L100-55, an anionic methacrylic acid polymer, has been studied for its use in solubility 
enhancement of poorly water soluble drugs with thermal processing into an amorphous solid 
dispersion as a common outcome. (94-97) In an ideal iteration, plasticizer would not be used to 
process the composition due to its potential negative effects on physical stability of the 
composition. (58) However, Eudragit L100-55 presents a challenge for thermal processing as it 
is known to undergo side chain degradation at 155°C with backbone structural loss starting at 
180°C. (98) 
 
In a study conducted by DiNunzio et al., compositions of Eudragit L100-55 with itraconazole 
were assessed by hot melt extrusion and KinetiSol to determine the impact of thermal processing 
on the polymer’s integrity. An initial finding of the study was the requirement of a plasticizer 
(triethyl citrate) was necessary to render compositions amorphous by hot melt extrusion but was 
not necessary for the same compositions by KinetiSol. The impact of this was a reduction of the 
glass transition temperature in the hot melt extrusion to dispersion to approximately 54°C 
whereas the material produced by KinetiSol had a glass transition temperature of 101°C. 
Ultimately, recrystallization of the hot melt extrusion composition was observed at accelerated 




Degradation of Eudragit L100-55 due to processing was also examined with specific focus on 
methacrylic acid functionality. Neat L100-55 was found to have 48.6% methacrylic acid units 
while the materials from hot melt extrusion and KinetiSol had 47.3% and 47.4% respectively. It 
is interesting to note that the hot melt extrusion sample was processed at 130°C (below the 
Eudragit degradation onset) while the KinetiSol process briefly went to 158°C. The degradation 
between the two samples was comparable but the KinetiSol process had the advantage of 
processing without a plasticizer which enabled it to have acceptable physical stability. 
 
1.4.2.3 Polyvinyl Alcohol 
 
A polymer whose application for amorphous solid dispersions that has not been extensively 
explored is polyvinyl alcohol (PVA). The reason for this is that PVA is difficult to process into 
amorphous solid dispersions by conventional means (spray drying and hot melt extrusion). Spray 
drying is challenging because the polymer is practically insoluble in organic solvents used in 
spray drying. (99) Thermal processing is difficult as PVA does not soften until reaching its 
melting point at which degradation onset can occur. (100, 101) However, PVA is an attractive 
polymer as it can modified by degree of polymerization (impacting solution viscosity) and the 
degree of hydrolysis. For example, PVA 4-88 has a 4% solution viscosity of 4 mPa*s and the 
functional groups have been 88% hydrolyzed (leaving 12% as acetate). (99, 102) This flexibility 
in substitution would theoretically allow for varying levels of sites for hydrophobic or 
hydrophilic interaction to aid in solubilizing poor soluble drugs. (56) 
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Brough et al. hypothesized that PVA could be processed into amorphous solid dispersions by 
KinetiSol. Itraconazole was selected as a model compound for the investigation. An initial study 
was carried out with 20% itraconazole to determine the ideal level of hydrolysis for solubility 
enhancement using PVA 4-38, 4-75, 4-88, and 4-98. While 4-98 showed some trace crystallinity 
upon processing, the other three compositions were found to be processable into amorphous solid 
dispersions by KinetiSol. Of these compositions, the 88% substituted grade had the greatest 
solubility enhancement by in-vitro dissolution testing. (102) A subsequent study investigated the 
impact of molecular weight (viscosity) and drug load on performance of 88% substituted grades 
of PVA. Specifically, grades 4-88, 5-88, 8-88, and 18-88 were evaluated by dissolution testing 
with PVA 4-88 having the best supersaturation properties of the 4 grades analyzed. Drug load 
dissolution studies showed that drug supersaturation was decreased with increasing drug load. 
(103) These studies demonstrated both the feasibility of processing amorphous solid dispersions 
containing PVA and the positive benefit for drug supersaturation with PVA 4-88. 
 
In another study by LaFountaine et al., the potential degradation of PVA when processed by 
KinetiSol was explored. Of particular interest was the degradation of PVA related to its degree of 
hydrolysis. PVA-ritonavir compositions were exposed to a range of rotational speeds (1000-2000 
rpm) and ejection temperatures (80-100°C). For all the processed samples except 1000 rpm/80°C 
ejection temperature, compositions were successfully rendered amorphous with respect to 
ritonavir. Ritonavir was separated out and in-solution 13C NMR analysis was conducted on the 
remaining sample. The analysis noted no change in the degree of hydrolysis of PVA. (56) 
However, it should be noted that the processing temperatures used in this study are significantly 
below the known degradation of PVA. 
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1.4.3 Other Applications 
 
1.4.3.1 Direct Compression 
 
To facilitate controlled release of a drug substance, approaches such as granules, pellets, and 
monolithic tablets have been utilized. (27, 104, 105) A key aspect is inhibition of 
recrystallization within the matrix due to water ingress. (106) Keen et al. studied the impact of 
glyceryl behenate, a modified release agent, in various hydrophilic dosage forms with one 
iteration comprised of monolithic tablets directly compressed from molten mass ejected from the 
KinetiSol process. The composition consisted of carbamazepine or itraconazole as model drugs, 
povidone K30 as the polymeric carrier, and glyceryl behenate which acted as a plasticizer as well 
as a modified release agent. In the case of itraconazole, a unique result was observed as zero-
order release was achieved for the molded tablet, even without glyceryl behenate present in the 
dosage form. The authors hypothesized that the hydrophobic nature of itraconazole acted as a 
release modifier. Additionally, it was suggested that there was an advantage in a directly molded 
dispersion over a compressed tablet as the compressed tablet would have pores in which water 
could ingress causing recrystallization of the drug in the matrix and blunted release. (38) Thus, 
the direct compression of molten mass into a monolithic tablet is another potential application of 




1.4.3.2 Mucoadhesive Dispersions 
 
Carbopol® is a cross-linked polyacrylic acid that has been utilized for delivery of molecules, 
predominantly peptides, to the intestinal region through the use mucoadhesion as an 
enhancement to delivery of challenging molecules. Specifically, the mucoadhesive patch adheres 
to the intestinal lining and promotes intimate interaction between the molecule being delivered 
and the intestinal membrane. (107-109) In relation to amorphous solid dispersions, Carbopol is a 
high melting point drug (110) which as noted elsewhere in this work poses a challenge for 
processing by hot melt extrusion. LaFountaine et al. hypothesized that KinetiSol could be 
utilized to process a binary composition of carbopol with a poorly soluble drug. Itraconazole was 
selected as a model due to its ease of processing and its extensive use as a model compound. 
(111) 
 
The authors processed binary compositions at drug loads of 10, 20, and 30% drug load. Trace 
crystallinity was observed at 40% drug load and this composition was excluded from future 
analysis. (111) Due to the hydrophobic nature of itraconazole, it was suspected that water ingress 
would be more limited in higher drug loads similar to the work molded tablet discussed in the 
previous section. (38) This was verified by contact angle analysis which showed not only did 
contact angle increase as a function of drug load, but also that KinetiSol processed material had a 
higher contact angle than equivalent physical mixtures. The authors posited that this was due to 
greater homogeneity of the samples with itraconazole dispersed at the molecular level. (111) 
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Investigation of the mucoadhesive properties of the dispersions was evaluated by measuring the 
adherence of compressed dispersion to freshly excised porcine intestine. Analysis was conducted 
by Texture Analyzer to determine the work of adhesion, or how strongly the tablet bound to the 
membrane. When sufficient wetting time was allowed (greater than 30 minutes with incubation), 
all dispersions adhered to the membrane. However, subsequent in-vivo analysis in a rat model 
showed lower itraconazole absorption than was expected. The authors attributed this to the lower 
pH in rats compared to humans as well as the low fluid volume. A necropsy study verified that 
the tablets adhered to the intestinal in the dosed rats as intended. Future analysis in a different 
model would be necessary to evaluate the efficacy of the delivery platform for delivering 
amorphous solid dispersions through mucoadhesion to the intestinal wall. (111) However, this is 
an attractive delivery platform for which KinetiSol is uniquely positioned to process. 
 
1.4.3.3 Porosity Enhancement 
 
For thermally based techniques, there is a growing interest in modifying the process of 
amorphous solid dispersion generation in a manner that increases the resulting product’s porosity 
and surface area. The increase in surface area from pores can lead to substantially increased 
dissolution rates, a desirable outcome for many dosage forms. (112, 113) A number of 
approaches have been employed with hot melt extrusion to create porosity in extrudate including 
sodium bicarbonate (114), supercritical carbon dioxide (115, 116) and nitrogen. (113) In a study 
conducted by LaFountaine et al., griseofulvin was processed with povidone K17 and HPMC E5 
into amorphous solid dispersions by both hot melt extrusion and KinetiSol. As shown in Figure 
1.19, porosity was apparent in x-ray computed tomography and scanning electron microscopy 
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images of the sample for the KinetiSol material. Further analysis showed that none of the hot 
melt extrusion products showed signs of porosity, but all the KinetiSol samples had at least some 
qualitatively observed porosity. It was hypothesized that the porosity was due to entrapped air in 
the molten mass and that the content could be modulated with modifications to quenching; 
however, this was not explored further. (89) 
 
 
Figure 1.19: Stereo Microscopy, X-Ray Computed Tomography, and Scanning Electron 
Microscopy Images of Amorphous Dispersions Generated by Hot Melt Extrusion 





As the number and complexity of poorly soluble drugs in pharmaceutical development increases, 
there exists increasing demand for solubility enabled delivery of these compounds. However, 
there is a growing void in this space as the conventional approaches of hot melt extrusion and 
spray drying now face limitations. KinetiSol has been shown to be an emerging technology that 
is beginning to fill this void. It has demonstrated its capability in handling high melting point 
and/or organic solvent insoluble APIs, thermally labile materials, and viscous polymers as well 
as the promise of other applications. These capabilities have expanded the formulation space 
beyond what was previously viable. 
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Chapter 2: Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous 




Vemurafenib is a poorly soluble, low permeability drug that has a demonstrated need for a 
solubility enhanced formulation. However, conventional approaches for amorphous solid 
dispersion production are challenging due to the physiochemical properties of the compound. A 
suitable and novel method for creating an amorphous solid dispersion, known as solvent-
controlled coprecipitation, was developed to make material known as microprecipitated bulk 
powder (MBP). However, this approach has limitations in its processing and formulation space. 
In this study, it was hypothesized that vemurafenib can be processed by KinetiSol into the same 
amorphous formulation as MBP. The KinetiSol process utilizes high shear to rapidly process 
amorphous solid dispersions containing vemurafenib. Analysis of the material demonstrated that 
KinetiSol produced amorphous, single-phase material with acceptable chemical purity and 
stability. Values obtained were congruent to analysis conducted on the comparator material. 
However, the materials differed in particle morphology as the KinetiSol material was dense, 
smooth, and uniform while the MBP comparator was porous in structure and exhibited high 
surface area. The particles produced by KinetiSol had improved in-vitro dissolution and 
pharmacokinetic performance for vemurafenib compared to MBP due to slower drug nucleation 
and recrystallization which resulted in superior supersaturation maintenance during drug release. 
In the in-vivo rat pharmacokinetic study, both amorphous solid dispersions produced by 
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KinetiSol exhibited mean AUC values at least two-fold that of MBP when dosed as a suspension. 
It was concluded that the KinetiSol process produced superior dosage forms containing 




Vemurafenib is administered in the treatment of the V600E mutation of the BRAF gene which 
leads to unresectable/metastatic melanoma in cancer patients (1, 2). It has also been 
demonstrated to reduce immunosuppression in addition to inhibition of tumor growth making it 
effective in tumor treatment. (3) The molecular structure of vemurafenib is shown in Figure 2.1 





Figure 2.1: Structure of vemurafenib. Reproduced with permission from (60). 
 
Molecular weight 489.93 Da 
Melting point 272°C 
BCS Classification II/IV 
Aqueous buffers (pH 3 and 7) < 0.1 µg/mL 
Fasted Simulated Intestinal Fluid (FaSSIF) < 2 µg/mL 
Log P 3.0 
Table 2.1: Molecular properties of vemurafenib. Adapted with permission from (4). 
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Due to its physiochemical properties, vemurafenib represents a significant challenge for oral 
delivery and it is classified as a Class II or IV drug in the Biopharmaceutical Classification 
System (BCS). The aqueous solubility of crystalline vemurafenib is <0.1 µg/mL and does not 
exhibit pH dependence in a biologically relevant range. In fasted simulated intestinal fluid 
(FaSSIF), the equilibrium solubility remains low at <2 µg/mL. Vemurafenib has a log P value of 
3.0 (4) which places it as a high permeability molecule with log P greater than 1.72. (5) This 
combination of parameters suggests that it should be classified as BCS Class II solubility 
challenged molecule. (6) However, in vitro testing found that vemurafenib demonstrated reduced 
permeability compared to a low permeability reference ranitidine in a Caco-2 cell model. (7) 
Thus, in practice it is a BCS Class IV solubility/permeability challenged molecule. (6) The 
molecular weight of vemurafenib is approximately 490 Daltons (4) which is just below the 
Lipinski rule of <500 Daltons. While not being counter to the multiple rule-of-5 criteria, the 
borderline nature of vemurafenib with multiple rules puts it in a class of molecules that are a 
challenge to formulate. (8) This difficulty is exhibited in clinical trial results. During initial phase 
I clinical trials, the crystalline form was found to be inadequate as the high dose patients were 
ingesting 1600 mg (32 capsules) of vemurafenib (9). Despite this very high administered dose 
(i.e., pill burden), efficacy was limited by low systemic drug concentrations, thus necessitating a 
solubility enhanced formulation to achieve the target therapeutic effect. Even with a solubility 
enhanced formulation, a clinical trial study found that 94% of the active vemurafenib was 
recovered in feces and 1% in urine, which was indicative of poor drug absorption. (10)  
 
Several options exist for dissolution rate and solubility enhancement to improve the oral 
absorption of compounds like vemurafenib. The Noyes-Whitney equation indicates that the 
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dissolution rate of a drug is proportional to the concentration gradient as well as the particle 
surface area. Thus, the dissolution rate can be increased by increasing the surface area of the 
material. Particle size reduction can be used to achieve this goal (11, 12) with nano-crystal 
technology as an example of a more modern approach for dissolution rate enhancement and has 
led to several commercial products. (13) However, due to its low equilibrium solubility, 
dissolution rate is not the primary cause for poor oral absorption of vemurafenib, and apparent 
solubility enhancement was expected to provide greater delivery benefit. Lipid based 
formulations represent another approach for drug delivery in which the drug is solubilized in a 
lipid vehicle and administered orally. (14) However, lipid based formulations are often 
challenged by high dose drugs (15) and as clinical trials demonstrated, vemurafenib efficacy 
requires a prohibitively high dose. Another approach is to modify the parent molecule to create a 
prodrug for improved absorption. In the case of vemurafenib, prodrugs are being tested in animal 
models (16); however, little data is available and these types of modification can require targeted 
radiation to activate the dose. (17) An effective way to overcome solubility challenges, 
particularly for drugs requiring a high dose, is the use of an amorphous form of active 
pharmaceutical in an amorphous solid dispersion. Of the drugs that are currently in development, 
approximately 90% are thought to be poorly water-soluble and would benefit from solubility 
enhancement. (18, 19) An amorphous solid dispersion is a carrier-drug system (e.g., polymer 
carrier) in which the drug molecules are dispersed in an amorphous state most typically within an 
amorphous carrier matrix. (20) However, there are limitations and challenges with amorphous 
dispersion formulations including: method of preparation, reproducibility, formulation into 
dosage forms, manufacturing scale-up and stability. (21) Despite these challenges, many studies 
have shown improved solubility and bioavailability for drugs administered in the amorphous 
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form as compared to the crystalline state. (18) Due to its high dose requirement and poor 
aqueous solubility, an amorphous solid dispersion of vemurafenib represents an attractive 
approach for oral delivery of this challenging molecule. 
 
Two predominant amorphous solid dispersion approaches are spray-draying and hot melt 
extrusion. Spray drying is a process by which the active pharmaceutical ingredient (API) and all 
excipients to be included in the amorphous dispersion are dissolved in a solvent system. This 
drug loaded solution is then sprayed as fine droplets into a drying chamber wherein solvent is 
quickly evaporated, resulting in an amorphous dispersion of the dissolved components. (22, 23) 
A significant limitation of the spray drying process is availability of a solvent in which all 
components demonstrate favorable solubility. Furthermore, the solvent system must be 
sufficiently volatile under typical spray drying conditions. To achieve suitable process 
efficiency, the solids load in the feed solution should be 5-50% (w/w) with >10% solids load 
being ideal. (22) This is particularly important for a high dose drug like vemurafenib in which 
large quantities need to be produced in order to meet the desired clinical and patient outcomes. 
Table 2.2 summarizes the solubility of vemurafenib in several organic solvents including the 
resulting calculated maximum drug % (w/w) in the feed solution and residual solvent 
classification of each solvent. As is apparent in the table, vemurafenib lacks suitable organic 
solubility in all of the listed common organic solvents except for dimethylacetamide (DMA). 
However, DMA is not suitable for the spray drying process due its high boiling point (166°C) 
(24) and it represents a safety and environmental hazard due to its residual solvent classification. 
(25) Thus, another amorphous solid dispersion approach is required for formulating 
vemurafenib.
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Organic Solvent Solvent Class Solubility (mg/mL) Maximum drug % (w/w) in Feed 
Dimethylacetamide 2 >500 53.4 
Methanol 2 4.57 0.6 
Acetonitrile 2 1.40 0.2 
Dichloromethane 2 1.95 0.1 
Isopropanol 1 3.56 0.5 
Acetone 1 <6 0.8 
Table 2.2: Organic solvent classification, vemurafenib solubility, and maximum spray-drying feed drug load. Adapted from (4, 22) 
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The other approach for amorphous solid dispersion production is hot melt extrusion. This is a 
thermal-based process for which melting points, glass transition temperatures, and component 
viscosities are critical parameters. (26) As a general rule of thumb, formulations that contain 
components with melting points greater than 200°C are challenging to process by hot melt 
extrusion as they require higher extruder temperatures, reduced drug loads, and/or the addition of 
a plasticizer. (27) Based on polymer viscosity and degradation onset, none of the common 
polymeric carriers examined by LaFountaine et al. had an extrudable window greater than 
200°C. (28) One specific example is hypromellose acetate succinate (HPMCAS), a polymer used 
to formulate amorphous solid dispersions with beneficial drug solubility properties related to 
interactions with acetyl and succinoyl groups. (29) However, HPMCAS has been shown to be 
sensitive to thermal degradation by melt extrusion leading to reduction in acetyl/succinoyl 
content as well as release of free acetic and succinic acid that may lead to drug degradation. (30) 
If drug load is reduced to accommodate the melt extrusion process, the result is increased pill 
burden for an already high dose drug to the patient. While plasticizers can be included during 
melt extrusion to lower the required processing temperature, the downside to their use is that 
they decrease the glass transition temperature of the system which can result in phase separation 
and eventually drug recrystallization. (31) Specific to vemurafenib, hot melt extrusion of 
vemurafenib was investigated by Albano et al. In their work, the maximum drug load of 
vemurafenib in a binary system was found to be only 10% (w/w) in a copovidone matrix. The 
drug load was increased to as high as 20-25% (w/w) only with the inclusion of 5-15% (w/w) 
glycerol monostearate, a plasticizer. (32) As it relates to drug load and plasticizer, these melt 
extrusion examples demonstrated the processing limits with vemurafenib by this technique. 
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Therefore, another amorphous solid dispersion approach was required in order to develop a 
suitable delivery platform for vemurafenib. 
 
Ultimately, a solvent-controlled coprecipitation process was developed for vemurafenib. 
Utilizing the high solubility of vemurafenib in dimethylacetamide, vemurafenib and HPMCAS 
(L grade) were dissolved in this solvent at 30% (w/w) drug load. This feed solution was slowly 
added to an anti-solvent, 0.01N hydrochloric acid, which simultaneously precipitated the drug 
and polymer as an amorphous solid dispersion. After washing and drying steps, the final 
resulting product, known as microprecipitated bulk powder (MBP), was collected, and it 
exhibited an approximately 30-fold increase in equilibrium solubility as compared to the 
crystalline form of the drug. (4) This material was used to manufacture the U.S. Food and Drug 
Administration approved product, Zelboraf®, which is administered as four 870 mg total weight 
tablets at a dosing frequency of twice daily. (1, 33) The effectiveness of this process with other 
model compounds and investigational molecules has also been explored by the inventors. During 
these studies, limitations with the process have been identified. From a drug perspective, the 
process is limited to molecules that are not susceptible to acidic degradation and have poor 
solubility in acidic media. This means that the process is not viable for many weakly basic drugs, 
many of whom have poor solubility in neutral gastrointestinal conditions where absorption is 
favored. Another significant limitation of the coprecipitation process is that it requires ionic 
polymers, which potentially restricts the choice of polymers that may be more favorable for 
solubility or stability. Finally, the final processing step involves the drying of aqueous solvent 
from the amorphous particles and a final water content of 2-3% is typically found. Both the 
drying process and the final water content can compromise the physical stability of the 
 90 
amorphous solid dispersion, and hence drug recrystallization is a significant concern. (34) While 
the solvent-controlled coprecipitation process is used to prepare a suitable amorphous solid 
dispersion for vemurafenib, there remains an unmet need for a process that works for drugs like 
vemurafenib but are not amenable to solvent-controlled co-precipitation. There also exists an 
opportunity to expand the formulation space of vemurafenib amorphous solid dispersions. 
 
One such process to address this need is KinetiSol. This process has been shown to work with 
drugs similar to vemurafenib that exhibit a high-melting point and low solubility in organic 
solvent. Figure 2.2 illustrates a process viability matrix for assessing processing technologies for 
APIs based on their melting point and solubility in organic solvent. In this scheme, vemurafenib 
fits in the upper-left quadrant for which hot-melt extrusion and spray-drying are not viable 
processes. Similar high melting point, low organic solubility drugs that have been processed by 
KinetiSol and fit in this category are meloxicam (35) and deferasirox (36). The process utilizes a 
fusion based approach where rotation of a set of protruding blades applies friction and shear 
forces to the material being processed. These energy inputs render the components amorphous at 
temperatures below the melting point of the compound and at fast solubilization rates. (37) Due 
to processing material at a lower temperature than the melting point of the drug, there is reduced  
degradation for thermally labile compounds. (38, 39) Processing times are significantly 
shortened and overall thermal exposure is lessened, especially as compared to hot melt extrusion 
(e.g., seconds versus minutes). (40) KinetiSol is also readily scalable as it was developed at a 
commercial scale and was scaled down for use in laboratory environments. (37) Unlike solvent-
controlled coprecipitation, the process is amenable to numerous types of polymers, which allows 
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for significant expansion of the formulation space. Thus, it was hypothesized that KinetiSol is a 
viable processing technology for the production of amorphous solid dispersions of vemurafenib. 
 
 
Figure 2.2: Amorphous solid dispersion viability matrix for API solubility and melting point. 








Vemurafenib API was obtained from Agno Pharma (Agno Pharma, Suzhou, Jiangsu, China). 
HPMCAS-LMP (L grade, medium particle size) was acquired from Shin-Etsu (Shin-Etsu 
Chemical Co., Tokyo, Japan). All chemicals used for MBP production were ACS grade and 
HPLC solvents were HPLC grade. FaSSIF dissolution media was prepared using FaSSIF, 
FeSSIF, and FaSSGF Powder (Biorelevant.com, Croydon, Surrey, UK) 
 
2.3.2 MBP Preparation: 
 
The process for MBP production provided by Shah et al. was used for production of amorphous 
vemurafenib material. (4, 34) Vemurafenib API and HPMCAS-LMP polymer were dissolved at 
15% w/w level in dimethylacetamide (DMA). The solution was slowly added 0.01N 
hydrochloric acid (HCl) with continuous stirring. It was held in the range of 2-5°C and the 
DMA:0.01N HCl ratio did not exceed 1:10 w/w. Precipitated solids were collected by vacuum 
filtration and washed in triplicate with cold 0.01N HCl followed by triplicate washes of cold 
water. The MBP material was dried in a Jeio OF-22G forced air convection oven (Jeio Tech, 
Daejeon, South Korea) until a constant moisture content was achieved. A IR-30 moisture 
analyzer (Denver Instrument Company, Arvada, Colorado, USA) was utilized to measure 
moisture content. The sample was milled partway through the drying process to aid in drying and 
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to reduce the particle size to the intended result. Table 2.3 defines the acronyms used in this 
paper. 
 
2.3.3 KinetiSol Processing: 
 
A KinetiSol compounder (DisperSol Technologies, Georgetown, TX) was used to generate 
vemurafenib amorphous solid dispersions. API and polymer were pre-screened through a #30 
mesh screen (≤300 µm) to rid the material of large particles. Material was prepared by hand 
mixing a blend of 30/70 vemurafenib/HPMCAS-LMP for 2 minutes and then charging into the 
compounder chamber. Inside the compounder chamber, a shaft with protruding blades was 
rotated a speed of 2400 rpm, without external heat addition, to impart frictional and shear forces 
to the sample material. Temperature of the mass was monitored using an infrared probe. When 
molten mass temperature reached a value of 180°C, the mass was rapidly ejected, collected, and 
pressed between two metal plates to rapidly quench the sample. This material was labeled KSD 




For <250 µm MBP and KSD samples, sample was broken into fragments and loaded into an IKA 
tube mill 100 (IKA, Staufen, Germany). Sample was processed for 1 minute at 5000 rpm. All 
milled material was subsequently passed through a #60 mesh screen (≤250 µm). Material >250 
µm was cycled through the mill with the same parameters and this process of milling and sieve 
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was repeated until all material passed through the screen. The resulting material is henceforth 




Abbreviation Full Term 
BCS biopharmaceutical classification system 
FaSSIF fasted simulated intestinal fluid 
API active pharmaceutical ingredient 
DMA dimethylacetamide 
HPMCAS hypromellose acetate succinate 
MBP microprecipitated bulk powder 
KSD KinetiSol solid dispersion 
KSD <250 KSD material <250 µm particle size 
KSD Cryo KSD material cryomilled 
XRPD x-ray powder diffraction 
mDSC modulated differential scanning calorimetry 
Tg glass transition temperature 
SEM scanning electron microscopy 
PSD particle size distribution 
BET Brunauer-Emmett-Teller theory 
Cmax,diss dissolution maximum concentration 
tmax,diss dissolution time of maximum concentration 
Cmax pharmacokinetic maximum concentration 
tmax pharmacokinetic time of maximum concentration 
AUC0→24 area under the plasma curve from 0 to 24 hours 
AUC0→∞ area under the plasma curve from 0 to infinity 
Table 2.3: Acronyms Used in Manuscript 
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For cryomilling, approximately 5 g of samples was broken into fragments and fed into a stainless 
steel cryomill tube with impactor. The sealed tube was loaded into a SPEX 6775 Freezer/Mill 
(SPEX SamplePrep, Metuchen, NJ) and lowered into the pre-filled liquid nitrogen bath. After a 
pre-cool time of 1 minute, samples were impacted by oscillation at 10 cycles per second for 2 
minute durations for a total of 10 iterations with 1 minute cooling time in between iterations. The 
sample was removed and used as is without further screening. The resulting material is referred 
to as KSD Cryo (see, Table 2.3). 
 
2.3.5 X-Ray Powder Diffraction: 
 
X-ray powder diffraction (XRPD) analysis was conducted using an Inel Equinox 100 X-ray 
diffractometer (INEL, Ardenay, France). Physical mixtures and milled, processed samples were 
loaded into aluminum sample holders and placed on a rotating stage. A Cu K Alpha radiation (λ 
= 1.5418 Å) x-ray tube was used with operating voltage of 42 kV and current of 0.8 mA. Data 
was collected with a curved radius detector in a 2Θ range of 2-110°. Data was collected and 
analyzed using Acquisition software (INEL, Ardenay, France). 
 
2.3.6 Modulated Differential Scanning Calorimetry: 
 
Thermal analysis was conducted by modulated differential scanning calorimetry (mDSC) with a 
Q20 Differential Scanning Calorimeter (TA Instruments, New Castle, DE, USA). Sample was 
prepared in a Tzero pan and sealed with Tzero lid. The target mass was approximately 5-10 mg 
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of sample per pan. Sample was equilibrated at a 35°C for 5 minutes after which the temperature 
was ramped at 3°C/minute to 300°C with a modulation of 0.3°C every 50 seconds. All data was 
collected with nitrogen as the sample purge gas. Samples were analyzed using Universal 
Analysis 2000 software (TA Instruments, New Castle, DE, USA). 
 
2.3.7 Physical Stability Study: 
 
Amorphous powders were loaded into aluminum X-ray sample holders and placed in a PH09 
stability chamber (Darwin Chambers Company, St. Louis, MO, USA). Samples were held at 
40°C/75% R.H. with no protection from moisture. Samples were removed and analyzed by X-
ray powder diffraction at time points of 0, 1, and 3 months using XRPD method described 
previously. Immediately after analysis, the samples were returned to the stability chamber for 
storage. 
 
2.3.8 HPLC Analysis: 
 
A high performance liquid chromatography (HPLC) method was developed for chemical 
analysis of vemurafenib amorphous dispersions utilizing the stability indicating method from 
Chabda et al in 2013 as a starting point for method development. (41) A Dionex Ultimate 3000 
HPLC system (Thermo Electron, Sunnyvale, CA, USA) was used for reverse-phase HPLC 
analysis. The HPLC column was a Kinetex 2.6u C8 100A column, P/N: 00C-4997-E0 
(Phenomenex, Torrance, CA, USA). Mobile phase A was a 0.1% aqueous phosphoric acid 
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solution and mobile phase b was degassed acetonitrile. A gradient profile with flow rate of 1.5 
mL/min was run for 16 minutes, the column was held at 40°C, and data was collected at a single 
wavelength of 254 nm. Samples were prepared at a nominal concentration of 0.1 mg/mL level 
with 80/20 Acetonitrile/Water as the standard/sample diluent. All samples were filtered through 
0.2 um, 13 mm ID nylon syringe filters with GMF pre-filter, P/N: 6870-1302 (Whatman, 
Piscataway, NJ, USA), prior to analysis. Samples chromatography was analyzed using 
Chromeleon software, version 7.1 (Dionex, Bannockburn, IL, USA). 
 
2.3.9 Scanning Electron Microscopy: 
 
Powder samples were adhered to stubs with conductive carbon tape and the interior of a small 
unmilled quenched fragment was mounted to a stub at an angle using a combination of carbon 
and copper tape. Stubs with sample were sputter coated with platinum-palladium under argon gas 
to a thickness of 15 nm in a Cressington 208HR Sputter Coater (Cressington, Watford, UK). 
Scanning electron microscopy (SEM) was performed on coated samples in a Zeiss Supra40 
Scanning Electron Microscope (Zeiss, Oberkochen, Germany). An accelerating voltage of 5 kV 
was used for all samples with the SE2 detector used for image capture. The stage was tilted so 




2.3.10 Particle Size Distribution: 
 
The particle size distribution (PSD) of the milled samples was analyzed in a Spraytec analyzer 
(Malvern Instruments, Malvern, UK). Samples were pre-loaded into gelatin capsules which were 
punctured to allow for sample exit and air flow escape. A feed pressure of 60 psi dry nitrogen 
was used to dose the powder into the unit. Acquisition was conducted with a 300 mm lens with 
acquisition triggered by transmission <98%.  
 
2.3.11 Surface Area Analysis: 
 
Particle surface areas were measured using a Monosorb Rapid Surface Area Analyzer model 
MS-25 (Quantachrome, Boynton Beach, Florida) and Brunauer–Emmett–Teller (BET) theory. 
For MBP and KSD Cryo samples, approximately 200 mg of material was loaded as 3 replicates 
into pre-dried U-tube glass sample cells. For the KSD <250 µm sample, approximately 1 gram of 
material was used. Samples were dried overnight at 35°C with outgassing under dry helium 
dioxide. Samples were re-weighed after outgassing. Surface area measurements were carried out 
by loading outgassed tubes into the analyzer one at a time and measuring the desorption phase of 
the absorption-desorption cycle. The sample surface area was divided by the outgassed sample 






Amorphous solid samples were analyzed for dissolution performance via non-sink dissolution 
testing. A Distek 2500 dissolution tester (Distek, North Brunswick, NJ, USA) was used for 
testing. The apparatus was set up per guidelines from United States Pharmacopeia 38, Chapter 
711 Dissolution, Apparatus 2. Fasted simulated intestinal fluid (FaSSIF), pH 6.5 dissolution 
media was prepared Biorelevant powder following manufacturer’s instruction. 500 mL of the 
media was added to each dissolution vessel and allowed to equilibrate to 37°C. Samples were 
prepared by filling size 00 hypromellose Vcaps (Capsugel, Morristown, New Jersey, USA) with 
amorphous material containing an equivalent of 40 mg of vemurafenib API. Capsule samples 
were prepared in triplicate for each sample. Sample addition to vessels was performed using 
stainless steel sinkers and paddle revolution was immediately begun at 75 rpm. Data collection 
was done with a Spectra fiber optic UV system (Pion Inc., Billerica, MA, USA) with data 
collected every 5 minutes from 200-700 nm. The system was standardized by generation of a 
calibration curve by which 2 mg/mL vemurafenib in DMA stock solution was spiked into a 
stirred vessel containing FaSSIF media. Data was analyzed by AU Pro software (Pion Inc., 
Billerica, MA, USA) by second derivate analysis and a range of 308-318 nm for integration. 
 
2.3.13 Pharmacokinetics in Male Sprague-Dawley Rats: 
 
In-vivo non-crossover pharmacokinetic analysis in a fasted male Sprague-Dawley rat model was 
conducted at Absorption Systems (Exton, PA, USA). Samples were suspended in 0.5% 
methylcellulose in water at a concentration of 5 mg of vemurafenib per mL of vehicle. A target 
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dose of 25 mg/kg was administered to each arm of the study. The cryomilled arm was 
inadvertently dosed at 21.9 mg/kg. Each arm consisted of 4 rats who were blood sampled at time 
points: 15, 30 minutes, 1, 2, 3, 4, 6, 8, 12, and 24 hours. Sodium heparin was added as an 
anticoagulant and blood samples were spun down to collect plasma. The plasma samples were 
analyzed by LC-MS/MS for vemurafenib content. Pharmacokinetic parameters were determined 
using Phoenix WinNonlin v7.0 (Certara, Princeton, NJ, USA).  
 
2.3.14 Statistical Analysis: 
 
Statistical analysis of pharmacokinetic parameters was performed using JMP Pro statistical 
software v13. All data was log transformed to stabilize variance. Data was first assessed for 
normality by Goodness of Fit (Shapiro-Wilk W Test). The non-parametric Kruskal-Wallis test 
was used to detect the presence of a statistically significant difference between the 3 samples for 
Cmax, AUC0→24, and AUC0→∞. When a difference was detected, a post-hoc multiple 
comparisons procedure Dunn’s test with the MBP sample as the control was used to check for 






2.4.1 MBP and KSD Processing 
 
MBP material was made per the methodology described above and that provided by Shah et al. 
(4)  Visual observations of the process conform to the images presented in additional work by 
Shah et al. describing the process with additional molecules. (34) Sample yields of fully 
processed and milled material ranged from 70-80%. MBP moisture content was measured to be 
2.76% by loss on drying. 
 
Sample was prepared by the KinetiSol process and the processing profile is seen in Figure 2.3. 
The total processing time for the run was 11.4 seconds. A 90 gram batch size was used for the 




Figure 2.3: KinetiSol profile for processing an amorphous solid dispersion of vemurafenib at 
2400 rpm 
 
Sample milled in the IKA mill and passed through a 250 µm screen was labeled KSD <250 µm 
and sample milled in the cryomill was labeled KSD Cryo. 
 
2.4.2 Solid State Characterization, Physical Stability, and Chemical Purity: 
 
MBP and KSD material were analyzed by XRPD and overlaid with neat vemurafenib API. An 
overlay of the scans is shown in Figure 2.4. Crystalline vemurafenib had major peaks at 2theta 
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values of 9.3, 15.2, 19.3, and 24.6. No peaks related to crystalline vemurafenib, or of any kind, 
were detected by XRPD. 
 
 
Figure 2.4: XRPD of neat vemurafenib, MBP, and KSD material (Scans are translated along the 
y-axis to aid in differentiation). 
 
MBP and KSD materials were analyzed by mDSC and the reversing heat flow thermograms and 
are depicted in Figure 2.5. The glass transition temperature (Tg) was determined for MBP, KSD 




Figure 2.5: Reversing heat flow thermograms for modulated differential scanning calorimetry of 
KSD and MBP materials. 
 
XPRD sample holders containing amorphous vemurafenib material were stored at 40°C/75% 
R.H. and were tested by the XPRD method at 0, 1, and 3 months. An overlay of the scans is 




Figure 2.6: XRPD of stability samples stored at 40°C/75% R.H. for 0, 1, and 3 months in open 
container (Scans are translated along the y-axis to aid in differentiation). 
 
Neat vemurafenib API, MBP and KSD samples were analyzed for purity based on % area by 





2.4.3 Particle Morphology: 
 
MBP and KSD samples were imaged for surface structure by SEM. The images are shown in 
Figure 2.7. Figure 2.7.a depicts a MBP particle which appeared to be solid particle with 
interconnected void space opening to the surface of the particle, similar to the spongy network 
structure as described by Shah et al. (4). This structure was observed across all MBP particles 
examined. Figure 2.7.b shows the KSD cryo material which contains a range of small particles 
sizes. These particles have smooth surfaces of uniform density without any visible pores. Figure 
2.7.c is the outer surface of a large KSD <250 µm particle. On this outer surface, two large 
exposed pores are observed, but the rest of the material is uniform and smooth in appearance. In 
Figure 2.7.d, the upper right region contains an image of the cross-section of the quenched, but 
unmilled KSD sample at significantly lower magnification the other images. In this cross-
section, many large, porous cavities are visible in the otherwise uniform mass. These cavities 
tended to aggregate near the edge of the cross-section. 
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Figure 2.7: Scanning Electron Microscopy images of MBP and KSD materials for a. MBP 
material, b. KSD cryomilled material, c. KSD material, < 250 µm. Dark circles are 
large cavities as observed in the cross section of Figure 2.7.d, and d. c.
 Unmilled cross section of quenched KSD material (upper right region, lower left 












Figure 2.7, cont. 
 
The D10, D50, and D90 values for particle size distribution are shown in Table 2.4. Specific 
surface areas are also listed. For the KSD <250 material, the surface area was below the limit of 
quantitation at 200 mg so the sample size was adjusted to 1 gram for sufficient material to 





Sample D10 (µm) D50 (µm) D90 (µm) 
Specific Surface 
Area (m2/g) 
MBP 2.39 ± 0.13 74.14 ± 1.68 220.90 ± 5.65 6.13 ± 0.05 
KSD <250 14.02 ± 0.84 132.74 ± 3.43 300.79 ± 2.62 0.20 ± 0.02 
KSD Cryo 2.14 ± 0.23 12.94 ± 1.42 78.96 ± 3.43 1.21 ± 0.06 
Table 2.4: Particle size distribution and specific surface area for MBP and KSD amorphous solid 
dispersions of vemurafenib 
 
2.4.4 In-Vitro Dissolution Testing: 
 
Dissolution testing was conducted on MBP, KSD <250 µm, KSD Cryo and physical mixture 
material that was hand-filled into capsules so that each capsule contained 40 mg of vemurafenib 
API per capsule. Dissolution profiles are shown in Figure 2.8. The MBP and KSD Cryo 
materials had similar initial release rates although the MBP released to a Cmax,diss of 74.4 
µg/mL at a tmax,diss of 3 hours, while the KSD Cryo material reached a Cmax,diss of 71.4 
µg/mL at a tmax,diss of 6 hours. However, vemurafenib from the MBP material precipitated at a 
faster rate than the KSD Cryo sample and had less drug in solution by the 5-hour time point. 
Meanwhile, the KSD <250 µm material released drug at a slower rate reaching a Cmax,diss 
value of 54.0 µg/mL at a tmax,diss of 16 hours. For hours 14 through 24, the KSD <250 sample 
had more drug dissolved in solution than either the MBP or KSD Cryo material. The KSD <250 
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µm was visually less turbid than the MBP or KSD Cryo vessels and this scattering was reflected 
in the UV profiles collected by the fiber optic probes. The physical mixture only had minimally 
detectable drug level in solution throughout the duration of the dissolution test. 
 
 
Figure 2.8: In-vitro dissolution of MBP and KSD amorphous solid dispersions and physical 




2.4.5 Pharmacokinetic Testing in Rats: 
 
Figure 2.9 shows the plasma concentration levels of vemurafenib dosed by oral gavage of 
vemurafenib suspensions in fasted male Sprague-Dawley rats. Both KSD samples exhibited a 
higher Cmax than the MBP material and maintained higher plasma levels than MBP for 24 




Figure 2.9: Vemurafenib plasma concentration in male Sprague-Dawley rats after oral 
administration of suspensions with target dosing of 25 mg/kg 
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Table 2.5 summarizes the calculated pharmacokinetic parameters from the plasma concentration 
data. Both KSD <250 and KSD Cryo materials had approximately 2-times the Cmax over MBP. 
The MBP material had a relative standard deviation (%RSD) of 24% which was similar to the 
KSD <250 material’s %RSD of 20% while the KSD Cryo material had half the variability at 
12%. For AUC, both KSD samples exhibited approximately 2.5-times the dose-normalized AUC 
value as compared to MBP. In this case, the % RSD was 29% for MBP, 63% for KSD <250, and 
56% for KSD Cryo. For the KSD Cryo sample, dose-normalized AUC was calculated with the 
administered dose of 21.9 mg/kg. tmax was similar for MBP and KSD Cryo at 2.0 and 1.8 hours 




Sample MBP KSD, <250 µm KSD, Cryo 
Dose (mg/kg) 25 25 20.9* 
tmax (h) 2.0 ± 0.8 3.5 ± 0.6 1.8 ± 0.5 





6,661 ± 1,910 17,607 ± 11,060 16,738 ± 9,340 
Table 2.5: Summary of calculated PK values for oral administration of MBP and KSD 
amorphous solid dispersions of vemurafenib in male Sprague-Dawley rats. 
*Suspension inadvertently dosed at 20.9 mg/kg instead of target 25 mg/kg. 
 
Statistical results for MBP and KSD Cryo AUC parameters were found to be non-normally 
distributed, p-values: 0.033 and 0.031, respectively for AUC0→24 and 0.033 and 0.029 
AUC0→∞. A statistically significant difference was not detected for either AUC parameter. A 
statistically significant difference was detected by the Kruskal-Wallis test for Cmax (p-value 
0.039). However, when MBP was compared to KSD <250 and KSD Cryo, no specific statistical 





2.5.1 Solid State and Chemical Purity: 
 
The XPRD data in Figure 2.4 exhibits no crystalline peaks in either the MBP or KSD materials. 
Specifically, the diffractogram for both dispersions is absent the crystalline 2-theta (°) peaks that 
are associated with vemurafenib crystallinity as observed in the XPRD diffractogram of the neat 
API. This indicates that the materially has been rendered substantially amorphous by both 
processes. DSC could not verify the absence of crystalline vemurafenib as its melting point of 
272°C exceeded the degradation onset of 204°C for HPMCAS (28) and polymer degradation 
events dominated the thermogram in the drug melting point region. However, mDSC was used 
for all amorphous solid dispersion samples to show a single Tg occurred at 99-101°C. The 
reversing heat flow thermograms are shown in Figure 2.5. These Tg values are consistent with 
the value obtained by Shah et al. for this MBP formulation, (4) indicating that the amorphous 
dispersions represent a single phase system with homogenous mixing of the drug and polymer. 
(42) Stability of the amorphous form is likely sufficient for both dispersions in light of literature 
recommending that samples be stored at least 50°C below the Tg of the system. (43, 44) This 
may allow storage of the amorphous dispersions up to ~48°C, which exceeds the typical 
accelerated storage condition of 40°C. In Figure 2.6, the stability data collected for MBP and 
KSD material showed no indication of crystallization peaks after 3 months at accelerated 
conditions in open container storage. The stable results show promise for the physical stability of 
the amorphous dispersions. 
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Comparison of the chemical purity of the amorphous dispersions to neat API indicates that 
vemurafenib undergoes minimal to no degradation when processed by both solvent-controlled 
coprecipitation and KinetiSol. MBP and KSD materials both had purity values 0.1% lower than 
neat API. These data demonstrated that KinetiSol can generate an amorphous solid dispersion of 
vemurafenib with a similar drug impurity profile to the solvent-controlled coprecipitation 
process utilized in manufacturing the commercial product. 
 
2.5.2 Particle morphology 
 
Based on the appearance of the resulting materials, it was suspected that differences in particle 
morphology exists between the two materials. The MBP material appeared sponge-like with a 
matrix of pores throughout the particles, similar to that described by Shah et al. (4). By contrast, 
the KinetiSol material appeared denser with no visible pores and was brittle when bent or 
compressed. The SEM images shown in Figure 2.7 confirm these observations. In Figure 2.7.a, 
the MBP material appears sponge-like with pores and channels running throughout the material, 
similar to images  presented by Shah et al. (4) Based on this observation, it is expected that the 
sample exhibits high surface area on a mass basis and, per the Noyes-Whitney equation, a rapid 
drug dissolution rate. By contrast, the KSD materials both showed particles that lacked extensive 
pore networks with outer surface tending to be exposed. However, in the cross section shown in 
Figure 2.7.d., small pores were exposed near the edge when the quenched material was broken 
into smaller fragments. These observations are consistent with results previously observed by 
LaFountaine et al. with griseofulvin amorphous solid dispersion made by KinetiSol with 
hypromellose and povidone polymers. (45) These pores are sufficiently large that they were 
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completely eliminated by particle size reduction in the KSD Cryo samples and few remained in 
the larger KSD <250 particles. These pores are likely a function of the quenching processing 
causing entrapped air in the molten mass to be pressed towards the edges of the material. The 
outermost layers of the quenched sample were in direct contact with chilled plates and 
temperature likely decreased below the glass transition of the mass before the entrapped air 
reached this region. This caused the boundary to solidify before the entrapped air escaped, thus 
creating pores. It is plausible that control of these entrapped air pockets could be used to increase 
the surface area and modulate release properties of KSD materials with manipulation of the 
quench step of the process being a primary driver for this modification. However, this was 
beyond the scope of this study and was not explored further here. 
 
The MBP, KSD <250, and KSD Cryo samples were milled to different particle sizes to 
investigate the effect of particle size on dissolution properties of the different materials. In a 
previous review by Huang and Williams, it was reported that for fusion-processed materials like 
KSD, milling is a significant contributor to surface area and release rate, whereas for porous 
materials like MBP and spray-dried dispersions, the pores were the primary driver of release rate 
with reduced impact from milling. (46) By particle size analysis, the MBP material had a D50 
value of 74 µm and a D90 value of 221 µm. These values are in agreement with the D50 and 
D90 reported for milled MBP material of 60 µm and 220 µm, respectively. (4) The KSD Cryo 
material was predominantly fines with a D10 value similar to MBP at approximately 2 µm, but 
with a D50 of 14 µm, which was 20% of the measured D50 value for MBP. The D90 value of 79 
µm was similar to the average diameter of a MBP particle. From this data and knowledge of 
particle appearances, the expectation was that reducing the KSD material particle size via cryo-
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milling would result in a KSD sample with similar surface area to the MBP material. To test for 
this, analysis with Brunauer-Emmett-Teller (BET) theory was used to verify the surface area 
difference between the amorphous dispersions. (47, 48) Table 2.4 shows that MBP material had 
a specific surface area of approximately 6.1 m2/g which agreed with reported values for MBP 
particles of 6.2 m2/g. (49) This is compared to the KSD Cryo sample’s specific surface area of 
approximately 1.2 m2/g. Despite an approximate 5-fold decrease in median particle size for the 
KSD Cryo material relative the MBP material, an approximately 5-fold increase in specific 
surface area was observed in the opposite direction of expectation based on particle diameter. 
Conventional evaluation of the Noyes Whitney equation indicates that the MBP material should 
release at approximately 5 times the rate of the KSD Cryo material. However, it is important to 
note that a substantial portion of the surface are of the MBP material is contained within the 
inner network of the material. Porous materials have been shown to have a dissolution rate 
slower than predicted by the Noyes-Whitney equation.  (50) Studies conducted by Korsmeyer et 
al. and Cardamone et al. demonstrated that during dissolution, polymer dissolved and saturated 
the inner channels of a porous material which created viscous media in these channels for which 
drug dissolution was significantly slowed. (51, 52) Thus, despite MBP’s high specific surface 
area, it was hypothesized that much of the gains in surface area are negated by this phenomenon. 
By contrast, the KSD <250 material was found to have a specific surface area of 0.2 m2/g. This 
surface area is congruent with results obtained by Dong et al. on similarly milled fusion-based 
material. (49) The expectation is that these particles can exhibit delayed release as compared to 
the MBP and KSD Cryo materials. 
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2.5.3 In-vitro and in-vivo performance testing 
 
In-vitro dissolution analysis of the samples revealed interesting and unexpected results. First, it 
should be noted that a physical mixture of vemurafenib with HPMCAS-L exhibited almost no 
drug dissolution with the maximal observed concentration of 1.13 ± 0.14 µg/mL. This makes 
apparent the need for a solubility enhanced formulation of vemurafenib. The MBP and KSD 
Cryo material had very similar initial dissolution rates but the MBP material reached maximum 
release before the KSD Cryo material (tmax,diss 3 hours versus tmax,diss 6 hours). By contrast, 
the KSD <250 showed extended release properties in this dissolution media with a mean 
tmax,diss of 16 hours. This supports the theory posited by Huang and Williams that particle 
properties and release rate for fusion processed material can be modulated by post-processing 
milling conditions. (46) However, MBP material precipitated at a faster rate and to a greater 
extent than the KSD materials. An explanation for MBP’s higher rate of precipitation is that 
within the interior of the particles, vemurafenib dissolved to saturation or supersaturation levels 
and remained at those levels due to lack of fluid exchange with bulk dissolution media. This lack 
of fluid exchange occurred because there was increased viscosity within the inner particle 
channels due to concurrent polymer dissolution as described by Korsmeyer et al. (51) In this 
microenvironment formed within the interior structure of the particle, vemurafenib was in 
contact with saturated or supersaturated media and the risk of recrystallization of undissolved 
vemurafenib increased. Additionally, in this microenvironment, supersaturated drug was 
susceptible to precipitation. Brouwers et al. described the following equation for the nucleation 
rate, Jn, of drug from solution: 





as a function of N0, the number of molecules per unit volume, υ, the frequency of atomic 
vibration, γns, the surface energy of the boundary, kb, the Boltzmann’s constant, T, the 
temperature, and S, the ratio of the drug concentration in solution to its equilibrium 
concentration. From this equation, a direct relationship exists between increases in the 
supersaturation ratio and resulting increases in the rate of nucleation. Once in bulk solution, these 
initial precipitates serve as sites for crystal growth with the greater number of nucleated particles 
in the MBP material resulting in increased precipitation rate. (53) By contrast, the KSD particles 
do not contain similar channels in which supersaturation can occur. Instead, the particles are 
expected to follow Noyes-Whitney behavior with drug diffusing away from the surface of the 
particle into bulk solution, thus minimizing localized supersaturation and nucleation risk. Based 
on the precipitation rate findings in this in-vitro study, in-vivo performance is expected to favor 
the KSD materials over the MBP particles. 
 
The observations from the in-vitro dissolution work were consistent with the results of the male 
Sprague-Dawley rat study. The mean AUC0→∞ values were approximately 2 and 2.5 times 
larger than MBP for the KSD Cryo and KSD <250 samples respectively with approximately 
double Cmax for both samples as well. In addition, the KSD samples exhibited reduced Cmax 
variability compared to MBP, especially in the case of the KSD Cryo material. However, 
contrary to expectation, the opposite was true for AUC with substantially increased variability in 
the KSD groups. Rats are known to have variable gastrointestinal transit times with colon arrival 
time occurring from approximately 6 to 16 hours in the fasted rat model. (54) For all dosed 
samples, tmax occurred earlier than the minimum gastrointestinal transit time, which means that 
Cmax was not impacted by gastrointestinal transit time. For MBP, the variability in Cmax and 
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AUC were in agreement (24% and 29%, respectively), which suggests that variability in rat 
gastrointestinal transit time did not impact this dose as absorption was completed by the time 
variable transit time was a concern. The observed in-vitro precipitation corroborates this 
conclusion as MBP’s increased precipitation negatively impacted drug absorption in rats with 
longer transit times as the amount of available drug to permeate was reduced. By contrast, the 
substantial increase in AUC variability in KSD <250 and KSD Cryo (63% and 56%, 
respectively) indicates that vemurafenib continued to be absorbed as the gastrointestinal transit 
time variability became a factor. Thus, the vemurafenib samples made by KinetiSol not only 
released to a greater maximal amount as exhibited by Cmax but also demonstrated behavior that 
correlates to prolonged absorption of the drug as compared to the MBP material. Additionally, it 
is important to note that the KSD Cryo sample was inadvertently dosed subpotently at 21.9 
mg/kg instead of the intended 25.0 mg/kg. Despite this lower dosing amount, its mean AUC 
approximately doubled the AUC of the comparator MBP material and had the highest overall 
Cmax of the test articles. Given these results, if translatable to humans, the data suggest that this 
formulation produced by KinetiSol can reduce patient dosing from 4 tablets to 2 tablets at each 
dosing event. For the KSD Cryo and MBP materials, the initial similar release rate observed by 
in-vitro dissolution showed good correlation in the tmax pharmacokinetic values with the 
materials exhibiting maximal values at 1.8 and 2.0 hours respectively. However, the in-vitro 
dissolution method was a poor predictor of release rate for the KSD 250 material that had a 
tmax,diss of 16 hours by in-vitro dissolution, but an in-vivo tmax of 3.5 hours. A statistically 
significant difference was identified for Cmax per the Kruskal-Wallis test, but a multiple 
comparisons procedure Dunn’s test was not able to determine which specific formulations were 
statistically different. The Dunn’s test p-values for Cmax of MBP vs. KSD 250 and Cryo were 
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0.07 and 0.06, respectively. No differences were detected in AUC. The root cause for this was 
likely due to variance in the results as the rat PK study wasn’t designed to have sufficient 
statistical power.  
 
Data for in-vitro dissolution and in-vivo pharmacokinetic testing demonstrated that, for the same 
formulation, KinetiSol produced a superior product relative to the MBP material from the 
solvent-controlled coprecipitation method. Beyond the processing improvement imparted by 
KinetiSol, it is important to note that KinetiSol has also shown that it expands the formulation 
space for vemurafenib and allows the processing with non-ionic polymers and surfactants 
previously restricted by the solvent-controlled coprecipitation process. (55) The non-ionic 
polymers may improve drug absorption in the proximal small intestine over the enteric carrier 
studied in this paper, and the surfactant component can also aid in enhancing drug dissolution 
and equilibrium solubility. (56) Coupling the KinetiSol processing gains demonstrated in this 
study with this expanded formulation space opens the opportunity for a significantly improved 
vemurafenib drug product with substantially reduced pill burden. Current investigations into 
vemurafenib combination products for the treatment of advanced melanoma (57-59) represent a 
growing area of interest that benefits from the gains derived from KinetiSol processing and 




This study found that KinetiSol processing produced vemurafenib amorphous solid dispersion 
material with similar purity and solid-state properties (amorphous and single-phase) as the 
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solvent-controlled coprecipitation process MBP. However, distinct differences were observed in 
the morphology of the particles produced by each of the processes with the KinetiSol generated 
materials representing dense particles without pores while the MBP material had significantly 
elevated surface area. These morphology differences resulted in intraparticle precipitation and 
subsequently more extensive precipitation of drug from the comparator MBP material. By 
comparison, the KSD particles exhibited reduced precipitation which led to improved dissolution 
and pharmacokinetic performance. Thus, KinetiSol produced a superior product that enhanced 
the delivery of the challenging vemurafenib molecule. 
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Chapter 3: Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base 




Ritonavir is an anti-viral compound that has also been employed extensively as a CYP3A4 and 
Pgp inhibitor to boost the pharmacokinetic performance of compounds that undergo first pass 
metabolism. For use in combination products, there is desire to minimize the mass contribution 
of the ritonavir system to reduce patient pill burden in these multi-agent products. In this study, 
KinetiSol® processing was utilized to produce an amorphous solid dispersion of ritonavir at 
double the drug load of the commercially available form of ritonavir and was subsequently 
developed into a tablet dose. The amorphous intermediate was demonstrated to be amorphous by 
x-ray powder diffraction and 13C solid-state nuclear magnetic resonance and an intimately 
mixed single-phase system by modulate differential scanning calorimetry and 1H T1/1H T1ρ 
solid-state nuclear magnetic resonance relaxation. In-vitro transmembrane flux analysis showed 
similar permeation rates for the KinetiSol-based tablet and the reference dosage form, Norvir®. 
In-vivo pharmacokinetic comparison between the two dosage forms resulted in equivalent 
exposure with approximately 20% Cmax reduction for the KinetiSol tablet. The performance 






The active pharmaceutical ingredient ritonavir was initially employed as an anti-viral agent and 
protease inhibitor in the treatment of advanced HIV-1. (1, 2) However, in subsequent years, the 
value of ritonavir has expanded to serve as a potent P-glycoprotein and CYP3A4 inhibitor. (3-5) 
Many compounds have been identified as CYP3A4 substrates and their pharmacokinetic 
performance is often limited as a result of metabolism. (6) Ritonavir has been utilized for co-
administration with other anti-HIV compounds such as saquinavir (7), indinavir (8), amprenavir 
(9), and lopinavir (10) to boost the pharmacokinetic performance of these molecules by 
inhibition of metabolism . Combination of ritonavir with anti-virals is a leading strategy in drug 
product development for the treatment of the hepatitis C virus (11, 12) and oncology products are 
being actively pursued as well. (13-15) 
 
Ritonavir is commercially available as the standalone marketed product, Norvir® tablet. This 
product includes an amorphous solid dispersion containing 100 mg of ritonavir processed by hot 
melt extrusion. In the amorphous solid dispersion, ritonavir is present at 15% drug load (w/w) 
with copovidone as the water-soluble polymeric carrier and sorbitan monolaurate as a surfactant. 
(16) The amorphous dispersion represents a 667 mg contribution to total tablet mass of 789 mg. 
(17) This represents a substantial mass, especially in the context of application as a 
pharmacokinetic boosting component. Thus, there is a driver to increase drug load to support a 
more patient-centric combination product, i.e., reduced tablet number and/or size. 
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KinetiSol® processing represents an emerging technology for the production of amorphous solid 
dispersions. The process utilizes high shear to rapidly process amorphous solid dispersions on a 
short time scale and at temperatures often below the melting points and/or glass transitions of the 
included components. (18) The process has the ability to produce amorphous solid dispersions at 
drug loads as high as 50% w/w. (19) This capability makes the KinetiSol process an appealing 
technology in the context of creating high drug load amorphous solid dispersions for use in 
combination products. For weakly basic molecules like ritonavir, anionic polymers have been 
demonstrated to be an attractive option as their acidic groups interact with and stabilize weakly 
basic molecules in solution. (20-22) The polymeric carrier hypromellose acetate succinate 
(HPMCAS) is of note as strong interactions between its succinyl and especially acetyl groups 
with weakly basic drugs promotes in-solution stabilization. (23) This benefit has borne out in 
numerous examples. (24-26) Ritonavir is both thermally (27) and acid labile (28) which limits 
the application of thermal processing techniques such as hot melt extrusion as ritonavir 
degradation would be accelerated during processing. However, KinetiSol processing has been 
demonstrated to process amorphous solid dispersions of compounds susceptible to thermal and 
acidic degradation. (29, 30) In a previous study, a ritonavir-HPMCAS amorphous solid 
dispersion was produced by KinetiSol processing to enhance the delivery of the CYP3A4 
metabolized AKBA compound at 30% drug load of ritonavir. (15) However, this study focused 
on the in-vivo AKBA exposure and did not explore broader application and utility of the 
ritonavir amorphous solid dispersion as a standalone dosage for CYP3A4 inhibition. In Figure 
3.1 from the initial study, a specific challenge was identified in that the reference Norvir 
amorphous intermediate behaved as a weak base during pH change dissolution testing (release 
predominantly in acid phase) but the ritonavir-HPMCAS amorphous solid dispersion behaved as 
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a weak acid formulation (release predominantly in neutral phase). For this new study, it was 
hypothesized that the amorphous solid dispersion of ritonavir and HPMCAS at double the drug 
load of Norvir and with different pH solubility profiles could be demonstrated to behave 
equivalently by in-vitro and in-vivo analysis. 
 
 
Figure 3.1: pH Change Dissolution of Crushed Norvir Tablets and Amorphous Solid Dispersion 








Ritonavir used in these studies was provided by Abbvie, Inc. (Chicago, IL, USA). Hypromellose 
acetate succinate (HPMCAS) used was Affinisol 912 granular grade acquired from Dow 
Chemical Company (Midland, MI, USA). Docusate sodium salt granular was acquired from 
Cytec Industries (Woodland Park, NJ, USA). All other excipients used in tableting or analysis 
were reagent grade except where otherwise noted. 
 
3.3.2 KinetiSol Processing and Milling: 
 
Ritonavir, HPMCAS, and docusate sodium salt were dispensed at a 30:65:5 ratio. Material blend 
was prepared by mixing components in a plastic bag by hand for approximately 2 minutes. 
KinetiSol processing was performed in a manufacturing scale KBC250 Batch Compounder 
(DisperSol Technologies, Georgetown, TX, USA). Batch size was 90 g and the sample was 
processed at 1500 rpm to an ejection temperature of 110°C. The ejected material was manually 
quenched between two metal plates. Quenched material was milled with a L1A Fitzmill 
(Fitzpatrick, Waterloo, ON, CA) at 9,000 rpm with blades forward and a 0.02” screen. Milled 
sample was passed through a #60 mesh (250 µm) screen. 
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3.3.3 X-Ray Powder Diffraction (XRPD): 
 
X-Ray powder diffraction was performed on a MiniFlex 600 (Rigaku, The Woodlands, TX, 
USA). Sample was packed into circular sample holders and leveled prior to loading in the 
instrument. The unit utilized a Cu alpha radiation tube powered at a voltage of 40 kV and a 
current of 15 mA. A D/teX Ultra high-speed detector was used for data acquisition. Method 
parameters used a scan rate of 5.0 degrees/minute at a step size of 0.02 degrees from 2.5 to 40 
2theta. Data was analyzed with the PDXL software package (Rigaku, The Woodlands, TX, 
USA). 
 
3.3.4 Modulated Differential Scanning Calorimetry (mDSC): 
 
Modulated differential scanning calorimetry was performed on a Q20 DSC unit (TA Instruments, 
New Castle, DE, USA). 5-10 mg of amorphous solid dispersion was evenly distributed in the 
bottom of a Tzero pan prior to compaction with a Tzero lid. Sample was equilibrated at 0°C for 5 
minutes. After equilibration, sample was heated at a rate of 5°C/minute to 220°C with 
modulation at an amplitude of 0.5°C and frequency of 30 seconds. Thermal analysis was 
performed with a purge gas of dry nitrogen. Data analysis was performed with Universal 




3.3.5 High Performance Liquid Chromatography (HPLC): 
 
Sample purity and dissolution concentration was analyzed by HPLC. Data was collected on a 
Dionex Ultimate 3000 instrument (Thermo Electron, Sunnyvale, CA, USA) with Chromeleon 7 
software used for data acquisition and analysis. HPLC grade water and acetonitrile were used for 
mobile phase A and B respectively. The column used for separation was an Acclaim™ 120, C18, 
5µm, 120A, 4.6x150mm, P/N: 059148 (Thermo Fisher Scientific, Waltham, MA, USA). For 
dissolution analysis, samples were run with isocratic 30/70 water/acetonitrile flowed at 1.5 
mL/minute for a 5 minute run time. For purity analysis, a 40 minute gradient was used with flow 
rate of 1 mL/minute. Purity sample was prepared at a nominal concentration 0.2 mg/mL and 
filtered through a 0.2 µm polyvinylidene fluoride (PVDF) syringe filter (Whatman, Piscataway, 
NJ, USA). Sample and column compartments were maintained at ambient conditions. An 
ultraviolet detector was used for data collection at a single wavelength of 240 nm. 
 
3.3.6 Solid State Nuclear Magnetic Resonance (SSNMR): 
 
Solid State Nuclear Magnetic Resonance was performed by Kansas Analytical Services 
(Loveland, CO, USA) on a Avance I Spectrometer (Bruker, Billerica, MA, USA). A 
Chemagnetics Apex probe refitted with a 7 mm Magic Angle Spinning (MAS) module 
(Revolutions NMR, Fort Collins, CO) was installed using 3-methylglutaric acid (MGA). 
Samples were packed into a 7 mm zirconia rotor. The instrument was operated at 399.67 MHz 
for 1H and 100.51 MHz for 13C. All experiments utilized MAS at 5 kHz, cross polarization 




Tablets were prepared per the formulation information provided in Table 3.1. A larger blend of 
material was prepared with 439 mg aliquots weighed out per tablet. Individual tablets were 
charged into a 04-17, 0.3126” x 0.4724”, modified oval die (Natoli, St. Charles, MO, USA) and 
compressed with a Manual Tablet Compaction Machine (GlobePharma, New Brunswick, NJ, 
USA) to a target compression pressure of 5,000 psi. Tablet dimensions were measured with a 
calibrated digital caliper and fracture force was measured by a TBH 125 Tablet Hardness Tester 
(Erweka, Heusenstamm, Germany) to calculate the tensile strength of the tablet. Tablet 
disintegration time was measured by dosing tablet to a beaker containing deionized water with 
mixing provided by an overhead impeller. 
 
Component Amount/Tablet (mg) Weight Percentage (%) 
KSD-RTV Amorphous Intermediate 333 75.9 
Microcrystalline cellulose 45 10.2 
Mannitol 30 6.8 
Croscarmellose 25 5.7 
Colloidal silicon dioxide 2 0.5 
Sodium stearyl fumarate 4 0.9 
Total 439 100 
Table 3.1: 100mg KSD-RTV Tablet Composition Containing 30% (w/w) Amorphous Solid 
Dispersion of Ritonavir 
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3.3.8 In-Vitro pH Change Dissolution: 
 
Tablets containing KinetiSol produced ritonavir amorphous solid dispersion were analyzed by an 
in-vitro pH change dissolution method against the reference tablet, Norvir®. Tablets containing 
100 mg of ritonavir were introduced into each vessel at the initiation of analysis. During the 
initial acid phase of the test, the dissolution media was 750 mL of 0.1N hydrochloric acid (HCl), 
pH 1.1. After 1 hour, the media was converted to 50 mM phosphate, pH 6.8 by rapid addition of 
0.2M sodium phosphate tribasic as described by Miller et al. (31) The media temperature was 
maintained at 37°C throughout the test. The dissolution apparatus was a Distek 2500 (Distek, 
North Brunswick, NJ, USA) set up in paddle configuration per the United States Pharmacopeia 
40, Chapter 711 Dissolution. Paddles were rotated at 50 rpm. 5 mL of sample was pulled via 
cannula at 30, 60, 65, 70, 75, 90, 120, 180, and 240 minutes. Pulled samples were filtered 
through a 1 µm glass membrane filter and diluted at a 1:1 ratio with acetonitrile. Diluted samples 
were analyzed by the HPLC method described previously. 
 
3.3.9 MacroFLUX Dissolution: 
 
Tablets containing KinetiSol produced ritonavir amorphous solid dispersion and the reference 
tablet Norvir were analyzed for trans-membrane flux by Pion Inc (Pion Inc., Billerica, MA, 
USA). A MacroFLUX dissolution setup was used for the analysis with a DT126 dissolution bath 
(Erweka, Heusenstamm, Germany). The donor compartment (dissolution vessel) utilized a media 
conversion dissolution from initially 800 mL of simulated gastric fluid (SGF), pH 1.6, to a final 
volume of 900 mL in fasted simulated intestinal fluid, (FaSSIF) pH 6.5. The acceptor 
 142 
compartment contained Acceptor Sink Buffer (ASB), pH 7.4. An Parallel Artificial Membrane 
Permeability Assay (PAMPA) artificial membrane infused with GIT lipid served as the barrier 
between the donor and receiver compartments. Drug concentration was monitored in both the 
donor and receiver compartments by a Rainbow fiber optic UV system (Pion Inc., Billerica, MA, 
USA) with 5 mm path length probe tips on the donor side and 10 mm path length probe tips on 
the receiver side. A calibration curve was generated from 0-80 µg/mL in SGF, FaSSIF, and ASB 
media. In the case of FaSSIF media, solubility limitations of the drug required drug pre-
dissolution in methanol with spiking into FaSSIF media to generate the curve. Total methanol 
content did not exceed 10% (v/v). Second derivative analysis was utilized to quantify ritonavir in 
solution with a range of 264-280 nm for quantification. Standard curves exhibited R2 values 
greater than 0.999. AU Pro software was utilized for all data analysis (Pion Inc., Billerica, MA, 
USA). 
 
3.3.10 Pharmacokinetics in Male Beagle Dogs: 
 
A pharmacokinetic study was conducted in male beagle dogs at Absorption Systems (Exton, PA, 
USA) to compare in-vivo performance of tablets containing KinetiSol produced ritonavir 
amorphous solid dispersion to Norvir. The study was non-crossover in design and each dog 
received one 100 mg tablet with three dogs per test article. All animals were fasted for 12 hours 
before dosing with food returned 4 hours post-dose. Tablets were provided by oral administration 
followed by a 40 mL flush with pH 2 acidified water. Blood samples were collected at 15 and 30 
minutes and 1, 1.5, 2, 3, 4, 6, 9, and 12 hours post-dose. Sodium heparin was used as an anti-
coagulant and samples were spun down to collect plasma. Plasma was analyzed by a LC-MS/MS 
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method for ritonavir content. Pharmacokinetic parameters were calculated using Phoenix 
WinNonlin v7.0 (Certara, Princeton, NJ, USA). 
 
3.3.11 Statistical Analysis: 
 
Statistical bioequivalence analysis between the test article, RTV-KSD, and the reference article, 
Norvir, was calculated following the procedures outlined in FDA Guidance for Industry: 
Bioequivalence Guidance. (32) All data was log transformed to stabilize variance in the sample 
data and preclude the need for distribution testing. Analysis of Variance (ANOVA) was utilized 
to determine the error mean square term. The 90% confidence interval was calculated for 
difference in log transformed mean of the reference and test articles and an alpha level of 0.05 
was used. The lower and upper bounds were back-transformed to provide the confidence interval 
for the ratio of the geometric mean of the RTV-KSD tablet over the geometric mean of the 
Norvir tablet. These confidence intervals were compared to the bioequivalence limits which were 
defined as 80-125%. Statistically significant bioequivalence was obtained when the complete 
confidence interval for a pharmacokinetic parameter resided in the range of 80-125%. The 






3.4.1 KinetiSol Processing and Chemical Purity: 
 
The KinetiSol processing profile for processing the amorphous solid dispersion of ritonavir is 






Figure 3.2: KinetiSol Processing Profile for Processing an Amorphous Solid Dispersion of 
Ritonavir at 1500 rpm 
 
Chemical purity by HPLC for the RTV-KSD sample was found to be 98.81%. The majority of 
the observed impurities is constituted in one peak at a relative retention time of 0.83 and at a 





















3.4.2 Solid State-Characterization – mDSC and SSNMR: 
 
When examined by XRD, the RTV-KSD amorphous solid dispersion lacked peaks associated 
with crystalline ritonavir and was fully amorphous (data not shown). For mDSC, the reversing 
heat flow thermogram and it is derivative with respect to time are shown in Figure 3.3 for the 
amorphous solid dispersion of ritonavir processed by KinetiSol. A single glass transition 
temperature (Tg) was observed at 61.16°C in the reverse heat flow plots. No melting point 





Figure 3.3: Modulated Differential Scanning Calorimetry of Amorphous Solid Dispersions 
Containing Ritonavir Made by the KinetiSol Process 
 
In the SSNMR analysis for 13C, regions of 150-160 ppm for ritonavir and 100-110 ppm for 
HPMCAS were determined to only contain peaks for those compounds. These regions were used 
for subsequent analysis. No peaks associated with crystalline ritonavir were observed. The 13C 





Figure 3.4: SSNMR 13C Spectra for Neat Materials and Ritonavir Amorphous Solid Dispersion 
with Isolated Regions Marked for the Primary Components, Ritonavir and 
HPMCAS 
 
Table 3.2 summarizes the data for 1H T1 and 1H T1ρ for each of the samples generated by 
KinetiSol processing. For 1H T1, the sample exhibited values of 1.70 ± 0.05 and 1.76 ± 0.05 
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seconds for ritonavir and HPMCAS, respectively. For 1H T1ρ, the sample exhibited values of 
7.68 ± 0.43 and 7.51 ± 0.19 seconds for ritonavir and HPMCAS, respectively. 
 
Sample 1H T1 (seconds) 1H T1ρ (ms) 
Docusate Sodium 1.15 ± 0.04 5.34 ± 0.14 
HPMCAS-MF 4.34 ± 0.13 6.82 ± 0.10 
Ritonavir 1.36 ± 0.04 87.35 ± 5.35 
RTV-KSD 
Drug: 1.70 + 0.05 
Polymer: 1.76 + 0.05 
Drug: 7.68 ± 0.43 
Polymer: 7.51 ± 0.19 
Table 3.2: SSNMR Relaxation Parameters 1H T1 and 1H T1ρ Spectra for Neat Materials and 




Using the KinetiSol processed amorphous solid dispersion, tablet blend was prepared per the 
formulation set forth in Table 3.1. Tablets were compressed at a target pressure of 2500 psi with 
modified oval dies and punches. On a representative tablet, calibrated calipers measured tablet 
dimensions as 7.95 mm wide by 12.02 mm long by 6.62 mm high. Tablet fracture force was 
measured as 146.1 N. The calculated tensile strength for the tablet was 1.38 MPa. Another 
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representative tablet was measured for disintegration time with the disintegration time in 
unbuffered water as 14 seconds. 
 
3.4.4 pH Change In-Vitro Dissolution: 
 
Figure 3.5 shows the pH change dissolution profile for the RTV-KSD tablet against the reference 
Norvir tablet. In the acid phase of the test conducted in 0.1 N hydrochloric acid, Norvir released 
to an average level of 82.2 µg/mL by the 60 minute pH change. In the same time frame and 
media, the tablet made from a KinetiSol processed sample released to an average level of 31.6 
µg/mL. During the neutral phase of the test at pH 6.8, the Norvir tablets precipitated from its 
acid maximum drug concentration to a maximum observed neutral concentration of 44.7 µg/mL 
at 15 minutes after pH change or 75 minutes total. The RTV-KSD tablets released to a maximum 
drug concentration of 70.4 µg/mL at 5 minutes after pH change or 65 minutes total. The RTV-
KSD tablet dissolution precipitated over time. In neutral pH 6.8 media, RTV-KSD tablets had a 
higher drug in solution concentration than Norvir through the 180 minute time point where RTV-
KSD had an in-solution ritonavir concentration of 36.3 µg/mL and Norvir had a ritonavir 




Figure 3.5: pH Change Dissolution of Tablet Made from KinetiSol Amorphous Solid Dispersion 
and Norvir Tablet 
 
3.4.5 MacroFLUX Assay: 
 
During the MacroFLUX assay, data and observations were collected on both the donor and 
receiver compartments. In the donor compartment, data collected in the neutral phase was not 


























pH 1.1 pH 6.8
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and to a lesser extent in RTV-KSD sample. Additionally, spectral shifts were observed in RTV-
KSD sample but were not observed in Norvir donor compartments. 
 
In the receiver compartment, appearance of drug was monitored throughout the test. During the 
SGF phase of the text (10-30 min.), the calculated average FLUX was 0.285 µg/(min. cm2) for 
Norvir and -0.015 µg/(min. cm2) for the RTV-KSD sample. In early phase of FaSSIF exposure 
(70-180 min.), the calculated average FLUX was 1.229 µg/(min. cm2) for Norvir and 1.145 
µg/(min. cm2) for the RTV-KSD sample. In late phase of FaSSIF exposure (800-1000 min.), the 
calculated average FLUX was 0.403 µg/(min. cm2) for Norvir and 0.420 µg/(min. cm2) for 





Figure 3.6: Ritonavir Concentration in Acceptor Compartment During pH Change Dissolution 
Conducted with MacroFLUX Permeability Apparatus 
 
3.4.6 In-Vivo Pharmacokinetic Testing in Fasted Dog Model: 
 
The average plasma concentration profiles for Norvir and RTV-KSD tablets are shown in Figure 
3.7. The calculated tmax for both samples was 1.5 ± 0.5 hours. Cmax for the Norvir sample was 
8490 ± 2316 ng/mL and the Cmax for the RTV-KSD tablets was 7037 ± 2713 ng/mL. Area 
under the curve at the last collected time point (AUC0→12) for each sample was calculated as 
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tablets, respectively. AUC extrapolated to infinity (AUC0→∞) for each sample was calculated as 
22612 ± 8927 hr*ng/mL for the Norvir tablets and 22115 ± 7494 hr*ng/mL for the RTV-KSD 
tablets, respectively. These parameters are summarized in Table 3.3. 
 
 
Figure 3.7: Ritonavir Plasma Concentration in Male Beagle Dogs After Oral Administration of 






























Sample Norvir KSD Tablet 
RTV-KSD 
Relative to Norvir 
Dose (mg) 100 100  
tMax (h) 1.5 ± 0.5 1.5 ± 0.5  








22612 ± 8927 22115 ± 7494 98% 
Table 3.3: Summary of Calculated Pharmacokinetic Values for Oral Administration of Ritonavir 
Tablets in Male Beagle Dogs For statistical bioequivalence analysis, the 90% 
confidence intervals for AUC0→12, AUC0→∞, and Cmax were 62-156%, 62-






3.5.1 Characterization of KinetiSol Produced Amorphous Intermediate: 
 
Conventional solid-state characterization was performed by XRD and mDSC to assess the 
system’s crystallinity and phases present, respectively. Both techniques confirmed that the 
amorphous solid dispersion produced by KinetiSol was amorphous with respect to ritonavir. 
mDSC also exhibited a single Tg at 61.16°C. The glass transition temperature of amorphous 
ritonavir is 50°C (33), amorphous HPMCAS is 122°C. (34) The subsequent equation has been 








where Tg is the glass transition temperature of the system, wi is the weight fraction of 
component i, and Tg,i is the glass transition temperature of component i. By this equation, the 
expected theoretical Tg for the ritonavir system processed by KinetiSol is 85°C. It should be 
noted that the equation proposed by Fox assumes that all components contribute equally to the 
glass transition of the system. Experimental results can be combined with the Gordon-Taylor 
equation to more accurately predict a system’s glass transition. (36) However, that analysis is 
beyond the scope of this work. The mostly likely cause for the reduction in glass transition 
against the theoretical value is that docusate sodium can act as a plasticizer in some systems (37) 
which can result in depression of the glass transition temperature. (38) In 1995, Hancock et al. 
established a guideline that the glass transition temperature of a system should be at least 50 
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degrees higher than the intended storage condition due to risk of phase separation and subsequent 
recrystallization of material during pharmaceutically relevant timelines. (39) However, this 
guideline was developed utilizing rapid crystallizer drugs which are kinetically unstable and the 
guideline has been updated in recent years. In 2017, Hancock established a classification for 
crystallization propensity based a molecule’s molecular weight and number of rotatable bonds. 
In the case of ritonavir (721 Daltons and 18 rotatable bonds), the classification describes it as 
having low propensity for crystallization. (40) Similar results were obtained in experimental 
work by Baird et al. classified ritonavir as a molecule with high glass forming ability and 
exhibited no recrystallization during heating. (41) Additionally, it has been demonstrated that 
weak base molecules like ritonavir have strong favorable interactions with anionic polymers like 
HPMCAS that promote improved thermodynamic stability of the system. (42, 43) 
Finally, Chokshi et al. reported an accelerated (40°C/75% R.H.) stability study of amorphous 
solid dispersions containing weakly acidic indomethacin and cationic Eudragit EPO with glass 
transition temperatures as low as 46°C remained physically stable whereas non-ionic polymers 
were unstable in the same timeframe.  All of these factors lead to the expectation that the RTV-
KSD amorphous solid dispersion described in this work would be physically stable, although 
verification of physical stability at accelerated conditions is a critical future study. 
 
When the reverse heat flow thermogram is examined, it was noted that there exist a number of 
disturbances in the signal beyond the primary Tg, including in the region where the Tg’s for 
HPMCAS and docusate sodium reside. Despite being broadly applied in analysis of amorphous 
solid dispersions, mDSC and XRD are limited by their limits of detection. In the case of XRD, 
the limit of detection is typically 0.9% (44) and for mDSC the limit of detection for phase 
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separation is 30 nm. Practically, this means that phase separation into domains smaller than 30 
nm will not be detectable by mDSC. (45) Additionally, the KinetiSol process is a short duration 
process typically lasting less than 30 seconds in total run time. In the case of the RTV-KSD 
amorphous solid dispersion, the maximum temperature of the process (110°C) is below the glass 
transition temperature of the polymeric carrier, HPMCAS (122°C). In the context of the 
thermogram appearance and the short duration, relatively low temperature KinetiSol process, a 
risk existed for an incompletely mixed system to exist and it was imperative to evaluate the 
amorphous solid dispersion with a more sensitive analytical technique. SSNMR is one such 
technique and it has been reported to have a minimum detectable domain size as low as 5 nm 
(46), compared to 30 nm for an ideal mDSC analysis. 
 
Initially, 13C SSNMR analysis was performed as a confirmatory test for detection of crystallinity 
in the RTV-KSD sample and no evidence of crystallinity was detected. Thus, the RTV-KSD 
sample is confirmed as amorphous. For the phase separation analysis, the relaxation times for 1H 
T1 and 1H T1ρ analysis were conducted on the samples with the values determined for both the 
API and the polymer. As is readily apparent from the data in Table 3.2 for both 1H T1 and 1H 
T1ρ, the API and polymer relaxation parameters are in good agreement with the values 
overlapping within 1 standard deviation of the reported results. Previous work with this 
technique and amorphous solid dispersions has shown that when 1H T1 values agree for two 
components that they are intimately mixed at the 20-50 nm domain size and for 1H T1ρ the same 
is true at the 2-5 nm domain size. (46) Thus, it was concluded that the RTV-KSD amorphous 
solid dispersion was an intimately mixed system by SSNMR analysis of both 13C and 1H 
relaxation times. It is important to note that a processing speed of 1500 rpm is on the low end of 
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the processing range for the KinetiSol process (1000-3400 rpm) (18) with a total processing time 
of less than 12 seconds. Additionally, the ejection temperature of 110°C is below the reported 
melting point of ritonavir (120°C) (27) and the glass transition temperature of HPMCAS 
(122°C). (34) In a study with the high melting point drug meloxicam, Hughey et al. proposed 
that the high shear imparted by the KinetiSol process reduced the Noyes-Whitney boundary layer 
thickness and enabled the drug to be solubilized but drug dissolution into the polymer as opposed 
to melting and mixing of the drug as seen in other thermal processes. (47) If SSNMR shows that 
the amorphous solid dispersion can be intimately mixed in a short, relatively low intensity 
process below the melting point and glass transitions of the formulation, then it is expected that 
amorphous solid dispersions processed at more aggressive conditions will be similarly intimately 
mixed.  
 
The chemical purity of the sample is similar to work previously reported for this amorphous 
composition. In that study, it was found that the one major degradant observed is also found in 
the reference tablet, Norvir, and at levels that would be beyond typical International Conference 
on Harmonization (ICH) guidelines. (15) Thus, it is expected that this degradant represents an 
impurity that has been qualified to higher acceptable limits via toxicology studies. 
 
3.5.2 In-Vitro Performance Characterization: 
 
When two formulations have different solubility properties, conventional dissolution 
methodologies are challenging to apply as was shown in previous work reproduced in Figure 3.1. 
(15) The employed pH shift methodology is often a frontline approach for assessment of the 
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performance a weakly basic formulation as it can simulate in-vivo transfer of the drug from the 
stomach to the intestinal compartment. (48) For the crushed reference Norvir product, the 
dissolution profile behaved as expected for the weakly basic ritonavir with extensive release in 
acid phase followed by substantial and rapid precipitation after conversion to neutral media. The 
non-ionic copovidone polymer did not impede the release of ritonavir during the acid phase of 
the test, as reported by Tho et al. (49) In the RTV-KSD amorphous solid dispersion, HPMCAS 
retarded the release of ritonavir during the acid phase of the test, followed by rapid dissolution of 
the drug and polymer when exposed to neutral phase conditions. Thus, the formulation released 
with a profile similar to a weak acid. After initial dissolution, HPMCAS slowed precipitation and 
helped maintain supersaturation, as reported elsewhere in literature. (24, 25) The disparity in 
performance across the test and in its individual phases suggests that conventional dissolution 
was inadequate when applied to the amorphous solid dispersions. Figure 3.5 shows a repeat of 
the analysis for tablet dosage forms and the analysis verified that the results hold for the final 
dosage form. 
 
The addition of an acceptor or absorptive compartment to dissolution analysis has been shown to 
increase the predictive power of the analysis. (48) A two compartment biphasic dissolution 
apparatus that employs an octanol as the acceptor phase has been extensively reported in the 
literature. (50-52) In a common configuration, the dosage form is loaded into a USP IV flow 
through apparatus which is connected as a loop to a USP II dissolution bath containing an 
aqueous lower phase and an octanol upper, absorption mimicking phase. Specific to weak bases, 
the USP IV flow through cell apparatus often exists as a closed loop containing acidified media 
that is opened to the neutral media in the USP II apparatus 30-60 minutes after test initiation. In 
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the context of the systems of interest in this study, the two-compartment biphasic approach is not 
without limitations. For certain formulations, octanol absorbed into the aqueous phase at 
concentrations of 1% or less has been shown limit release of the drug to as low as 40% release 
compared to media without absorbed octanol. (53) Octanol absorption into media is particularly 
problematic when using biorelevant media (e.g. FaSSGF, FaSSIF or FeSSIF) as the surfactant 
enriched media can promote incorporation of octanol. (54) Specific to HPMCAS and octanol, a 
study by Sarode et al. reported high levels of aqueous supersaturation of itraconazole:HPMCAS 
amorphous solid dispersion in a single-phase dissolution, but nearly zero partitioning of 
itraconazole into the octanol layer of a separate biphasic dissolution. (55) The lack of 
partitioning of this formulation is surprising as itraconazole:HPMCAS formulations have been 
extensively studied and shown to have superior in-vivo performance over many other polymeric 
carriers. (25, 56) Additionally, it has been reported that two-compartment portion of the setup 
can restrict or delay the release of formulations that are pH dependent and/or erode. (53) In the 
case of RTV-KSD and the reference Norvir, it would be expected that ritonavir from Norvir 
would undergo significant dissolution during the acid phase of the test and be ready for transfer 
into the neutral compartment at the end of the 30 minute closed loop phase of the test. By 
contrast, RTV-KSD would undergo minimal dissolution during the closed loop portion of the test 
and would have a delay in release as the HPMCAS particles would slowly dissolve as the pH is 
gradually increased in the USP IV cell. Finally, in other studies, weak acid molecules have 
received different treatment from weak bases with their entire test conducted in neutral media. 
(57) The same application should be considered for a formulation that behaves like a weak acid. 
A biphasic test that included the acid phase would be expected to bias results towards Norvir 
whereas a test conducted without acid phase would be expected to bias results towards RTV-
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KSD. Thus, another in-vitro test was deemed necessary for comparison of the formulations in 
this study. 
 
Another example of an absorptive compartment joined to a conventional dissolution is 
transmembrane flux. One example is the MacroFLUX apparatus from Pion Inc. In this 
configuration, a traditional dissolution apparatus is used and an acceptor compartment containing 
acceptor sink media is lowered into the top of the media in the dissolution vessel. A parallel 
artificial membrane permeability assay (PAMPA) barrier forms a boundary between the 
dissolution media and the acceptor compartment and drug concentration in the acceptor 
compartment is monitored by a UV probe. (58) The PAMPA membrane has been demonstrated 
to correlate well with octanol-water partitioning measurements. (59) For the systems at hand, the 
advantages to a transmembrane flux analysis is that it removes octanol absorption into aqueous 
medias as a potential issue and eliminates the need for multiple compartments to facilitate pH 
shift during analysis. However, a limitation that exists for membrane systems like FLUX is that 
the limited surface area of the membrane is not representative of the total absorption and extent 
of mass transfer of the system being studied. (60) However, the rate of transfer across the 
membrane can be assessed and used to compare absorption rate of drug. (61) This form of 
analysis was expected to be able to compare the formulations of interest without biasing the test 
to favor one formulation or the other. 
 
A MacroFLUX apparatus with conversion from SGF to FaSSIF after 30 minutes was used to 
collected data on both donor and receiver compartments for dissolution and absorption of RTV-
KSD and the Norvir reference tablet. In the donor compartment, Norvir released more rapidly 
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and to a greater extent than the RTV-KSD sample during the 30 minute SGF phase. After pH 
change, both formulations exhibited extensive turbidity, although it was observed that the RTV-
KSD had a delayed onset of turbidity and to a lesser extent. This observation corroborated the 
pH change dissolution testing. However, the donor compartment data is not reliable due to high 
levels of Tyndall turbidity. The acceptor compartment showed slight flux (0.285 µg/min/cm2) of 
ritonavir from the Norvir sample whereas the RTV-KSD sample had a slightly negative flux 
value within the baseline drift of the of the analysis. This was expected from the known release 
profiles of the two formulations in acidified media. After media conversion, flux increased for 
Norvir and RTV-KSD to 1.229 µg/min/cm2 and 1.145 µg/min/cm2 during early the early stage 
of FaSSIF analysis and 0.403 µg/min/cm2 and 0.420 µg/min/cm2 during the late stage of FaSSIF 
analysis. These represented RTV-KSD flux ratios of 94% in early stage FaSSIF and 104% in late 
stage FaSSIF. Based the measured rate of drug presentation in the acceptor compartment, it was 
expected that the two dosage forms should behave similarly in-vivo. 
 
3.5.3 In-Vivo Pharmacokinetic Testing in Dogs and Statistical Analysis: 
 
When selection of an in-vivo model was considered, similar issues related to differences in the 
formulations surfaced. Human gastric pH in the fasted state has been reported to range from 1-5 
with the most common values occurring in the range of 1-2. (62-64) Compared to humans, dogs 
are poor acid secretors which can result in differences in performances for pH dependent 
formulations. (65) In the case of male beagle dogs, gastric pH has been reported across a wide 
range from 0.9-8.3, with most results occurring at extremes of the range. (62, 66) This range can 
have a significant impact on formulation performance, particularly for compounds exhibit pH 
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dependent solubility (66), such as ritonavir. To overcome high pH animals and variability in the 
dog model, there’s a long history of dog PK testing in literature involving pretreatment with 
pentagastrin and histamine to control dog gastric pH. (4, 66, 67) While the in-vivo effects of pH 
modification on gastric conditions have been reported extensively in literature (65), there has 
been minimal in-vivo work to evaluate the effect of gastric pH modifiers on pH in the upper 
intestinal region of the animal model where significant absorption often occurs. However, an in-
vitro analysis conducted with an artificial stomach and duodenum dissolution model 
demonstrated that buffered phosphate pretreatment (to represent in-vivo pentagastrin 
pretreatment) showed a reduction in the duodenum compartment pH to less than 5, and as low as 
3, for approximately 1.5 hours. By contrast, an acidified suspension lowered duodenum pH for 
substantially less time, in the order 10-20 minutes. (68) This observed effect would be expected 
to boost duodenum performance of a formation with weakly basic behavior (such as Norvir) 
while limiting the performance of a weakly acidic formulation (such as RTV-KSD) in the same 
region. 
 
To overcome these challenges, the conducted study utilized a 40 mL post-dose acidified water 
(pH 2) flush. The acidified flush was expected to reduce the stomach pH initially to allow for 
rapid dissolution of the Norvir tablet without a significant cascading pH effect that would lower 
pH in the duodenum region and blunt the release of RTV-KSD in this region. The study results 
found the pharmacokinetic data in good agreement between the formulations with equivalent 
tmax values of 1.5 hours and a RTV-KSD:Norvir AUC ratio of 97-98%. These congruent results 
were obtained despite formulating the dose to perform as a weak acid. A reduction in Cmax was 
observed at 83% for RTV-KSD relative to Norvir. This could represent an advantageous 
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situation for RTV-KSD as peak concentration (Cmax) reduction while maintaining overall drug 
exposure (AUC) is an important means of reducing or eliminating drug side-effects. Specific to 
ritonavir, neurological and gastrointestinal side-effects have been correlated to Cmax of the 
pharmacokinetic performance. (69) 
 
Statistical analysis was performed to assess the RTV-KSD formulation for bioequivalence to the 
Norvir reference product. The United States Food and Drug Administration has established that 
formulation is deemed bioequivalent when the AUC and Cmax are statistically within 80-125% 
of the reference product. (32, 70) In the case of this analysis, the 90% confidence intervals for 
Cmax and AUC were not contained within the bounds of the 80-125% requirement. However, it 
should be noted that the pharmacokinetic study was not sufficiently powered to demonstrate 





A drug loading enhanced amorphous solid dispersion of ritonavir was produced by the 
KinetiSol® process. The formulation demonstrated adequate chemical purity, a lack of 
crystallinity, and homogeneity as a single-phase system. Additional analysis conducted by 
SSNMR showed that the amorphous solid dispersion was intimately mixed to a 2-5 nm scale 
despite a processing time on the order of second and at temperature below relevant thermal 
transitions for the formulation components. After formulation into a tablet, in-vitro analysis by 
transmembrane flux resulted in similar rates of drug transfer across a PAMPA membrane when 
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compared to the commercially available Norvir tablet. In-vivo pharmacokinetic analysis in a 
fasted dog model showed congruent exposure between the two dosages with approximately 20% 
Cmax reduction. The KinetiSol-based dosage form demonstrated essentially equivalent 
performance but with a reduction in tablet mass from 789 mg to 439 mg, a reduction of 
approximately 45%. The mass reduction is directly beneficial for combination product 
applications to reduce pill burden, thereby improving patient convenience and compliance. 
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Chapter 4: The Utility of Pharmaceutical Lubricants in Amorphous Solid Dispersions as a 




In this work, an investigation was conducted on an unexpected in-vivo benefit observed with the 
inclusion of the lubricant magnesium stearate in an amorphous solid dispersion. Lubricants like 
magnesium stearate are understood to negatively affect dissolution and pharmacokinetic 
performance of poorly soluble drugs and are used sparingly or avoided altogether. In this study, 
amorphous solid dispersions containing various lubricants in the amorphous solid dispersion 
were evaluated for their impacts on in-vitro and in-vivo drug performance. Improved dissolution 
was observed when the weakly acidic deferasirox, the neutral etravirine, and the weakly basic 
ritonavir drug molecules. Solubility benefits were observed with a large range of lubricants 
encompassing pharmaceutical fatty alcohols, fatty carboxylic acids, glyceryls, stearates, and 
other lubricants. Benefits were demonstrated with amorphous solid dispersions processed by the 
fusion process of KinetiSol dispersing and melt-quenching. In one example, the positive effect of 
a lubricant was observed when included in addition to a traditional surfactant. Positive effects 
observed in-vitro were corroborated by an in-vivo pharmacokinetic study with etravirine in 
fasted male beagle dogs. It was concluded that pharmaceutical lubricants can be utilized for 






In the current pharmaceutical development world, it is estimated that as high as 90% of drug 
molecules in development are solubility challenged. (1) The same holds true for approved drugs 
where drugs approved in 2012 were on average ten times less soluble than drugs approved in 
1983. (2) To address these solubility challenged molecules, amorphous solid dispersions are 
applied with increasing frequency to allow for efficacious delivery of these molecules. As 
illustrated in Figure 4.1, only 4 orally administered amorphous drug products were approved 
prior to 2007, but in the time interval 2007-2017 there have been 19 approved amorphous oral 
dosage forms. (3) Additionally, a March 2015 survey found that there were at least 76 
amorphous solid dispersion products in development pipelines at that point in time. (4) Despite 
the extensive use of amorphous solid dispersions in current product development, new chemical 
entities are increasingly outside Lipinski’s rule-of-5 (5, 6) and attrition rates of remain high. (7) 
Even when an approved amorphous solid dispersion product is successfully launched, patient pill 
burdens remain high in some instances. Examples such as Zelboraf® (4 tablets, twice daily) (8) 
and Incivek® (2 tablets, thrice daily). (9) In the case of Zelboraf, there is evidence that the need 
for a high dose is at least partially caused by poor absorption of vemurafenib as 94% of the dosed 
active substance is recovered in fecal matter. (10) Thus, in addition to enabling drug delivery 
through generation of an amorphous solid dispersions, there is a demonstrated need to expand 




Figure 4.1: Approved Products Developed as Amorphous Solid Dispersions or Nanocrystals 
Reproduced from (3) with permission. 
 
In a study of amorphous solid dispersions of deferasirox by the authors, a surprising positive 
result was obtained when the lubricant magnesium stearate was included in the amorphous solid 
dispersion. Initially, amorphous solid dispersions containing deferasirox with polymers as 
copovidone or copovidone/Eudragit® L100-55 were prepared by KinetiSol processing. To 
increase product yield, magnesium stearate was included as an optional lubricant in both 




Phase Component Lot 25 Lot 52 Lot 28 Lot 53 
Amorphous 
Intermediate 
Deferasirox 40% 40% 40% 40% 
Copovidone 20% 19.8% 40% 39.6% 
Methacrylic 
Acid and Ethyl 
Acrylate 
Copolymer 
20% 19.8% 0% 0% 
Magnesium 
Stearate 





13% 13% 13% 13% 
Croscarmellose 
Sodium 
6% 6% 6% 6% 
Colloidal 
Silicon Dioxide 
0.5% 0.5% 0.5% 0.5% 
Magnesium 
Stearate 
0.5% 0.5% 0.5% 0.5% 
Table 4.1: Tablet Formulation Information for Deferasirox Tablets Prepared for Dosing in Dog 
Pharmacokinetic Study. All tablets prepared 900 mg total weight with 360 mg of 
deferasirox (active pharmaceutical ingredient). Amorphous intermediate prepared 
by KinetiSol process. 
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To assess the effects of lubricant inclusion in the amorphous solid dispersion, an in-vivo 
pharmacokinetic study was conducted in fasted male beagle dogs. Blood plasma concentrations 
are shown in Figure 4.2 and the pharmacokinetic parameters are summarized in Table 4.2. 
 
 
Figure 4.2: Deferasirox Plasma Concentration in Dog Pharmacokinetic Study Dosed at 360 mg 




PK Parameter Lot 25 Lot 52 Lot 28 Lot 53 
AUC (ng*hr/ml) 262,333±61,028 394,815±101,967 283,375±39,668 409,369±133,071 
Cmax (ng/ml) 48,550±17,337 75,750±25,364 59,775±5,480 88,300±32,129 
tmax (hr) 1.75±0.29 2.13±0.63 2.00±0.82 1.50±0.41 
Table 4.2: Pharmacokinetic Parameters From Dog Pharmacokinetic Study Dosed at 360 mg of 
Deferasirox Per Tablet with 1 Tablet Per Dog 
 
For both polymeric systems, the inclusion of lubricant resulted in a 44-50% increase in average 
AUC and a 48-56% increase in average maximum plasma concentration. 
 
The results obtained in the deferasirox-lubricant in-vivo study were unexpected and surprising. 
Lubricants are well established to be detrimental to performance of poorly soluble drugs when 
utilized as lubricants in their crystalline form. (12-14) The negative effect on dosage 
performance has been observed with increasing lubricant concentrations as shown in dissolution 
profiles in Figure 4.3. As magnesium stearate concentration was increased, dissolution rate and 




Figure 4.3: Effect of Magnesium Stearate Concentration on Dissolution Performance of 
Nitrofurantoin Tablets Granulated with Starch Paste. Magnesium stearate 
concentration (% w/w): closed circles – 0.5%, open circles – 1.0%, closed squares – 
1.5%, open squares – 2.0%, open triangles – 3.0%. Reproduced from (32) with 
permission. 
 
In the case of stearate lubricants, the effect has been demonstrated to be dependent on the 
particular stearate lubricant utilized as shown in Figure 4.4. In this analysis, magnesium stearate 
was found to be the worst-case lubricant for SQ37256 performance which further increased the 




Figure 4.4: Effect of Various Lubricants on 0.1N Hydrochloric Acid Dissolution Performance of 
SQ32756. Closed circles contain no lubricant, open circles contain calcium stearate, 
open squares contain zinc stearate, and closed squares contain magnesium stearate. 
Reproduced from (33) with permission. 
 
Sodium stearyl fumarate, another lubricant, is promoted as an alternative to magnesium stearate 
with reduced negative effects on drug delivery (15-17), but many examples exist where its 
presence also limited drug performance. (18-20) Another interesting aspect of the deferasirox 
with magnesium stearate example is that the large performance benefits were observed with the 
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inclusion of only 0.5% w/w lubricant in amorphous solid dispersion. There was a significant 
benefit to formulation enhancement without a corresponding substantial increase in mass of the 
dosage form. This aspect is important for high dose drugs where patient pill burden is already a 
significant challenge. (21) In this instance, magnesium stearate greatly improved the 
performance of the deferasirox formulation and opportunity was recognized to apply it and 
similar molecules as formulation solutions in amorphous solid dispersions. 
 
It was hypothesized that water insoluble molecules with properties like magnesium stearate 
could be used to enhance the in-vitro and in-vivo performance of poorly water soluble drugs 
when co-formulated internally in an amorphous solid dispersion. To test the hypothesis, there 
were a several key areas to consider. First, it was imperative to assess that the inclusion of 
lubricants in the amorphous solid dispersion was beneficial to multiple classes of active 
pharmaceutical ingredients. To meet this need, deferasirox was selected as a weakly acidic 
molecule, ritonavir was selected as a weakly basic molecule, and etravirine was selected as a 
non-ionic molecule. Second, it was important to assess the breadth of molecules that could be 
applied in this manner. Molecules with properties like magnesium stearate and their 
classifications are discussed in the following paragraph. Another important consideration was if 
the performance gains could be realized in systems that already benefited from the inclusion of a 
surfactant to promote solubility enhancement. Finally, since the initial surprising result was 
discovered on amorphous solid dispersions processed by KinetiSol, it was deemed important to 
verify that the performance enhancement is not limited to amorphous solid dispersions prepared 
in this manner and that an amorphous solid dispersion processed by another technique could 
impart a similar effect. However, it is important to note that a review of magnesium stearate and 
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compounds with similar properties found that all of these compounds are practically insoluble in 
common organic solvents. Thus, solvent-based approaches represented limited opportunity for 
solubility enhancement through this formulation modification strategy and were not pursued. 
 
When magnesium stearate was examined to identify similar molecules for assessment for 
amorphous solid dispersion performance enhancement, four criteria were applied: insoluble in 
water, melting point amenable to thermal processes, crystalline, and non-polymeric. After 
extensive review, several pharmaceutical additives were identified that met these criteria and 
were further classified based on common functional groups. These groups were fatty alcohols 
(Table 4.3), fatty carboxylic acids (Table 4.4), glyceryls (Table 4.5), stearates (Table 4.6), and 
three other compounds (Table 4.7) that did not fit the functional categories of the other 
compounds. Excluding menthol, all other compounds included long fatty carbon chains with one 
or more functional groups at the head (e.g. hydroxyl for fatty alcohols). Thus, if the carbon chain 
is important to the solubility enhancing performance of these lubricants, then menthol could 




Component Aqueous Solubility 
Physical Form 
@ Room Temperature 
Melting 
Point (°C) 
Myristyl Alcohol Practically insoluble Waxy solid 38 
Cetyl alcohol Practically insoluble Waxy flakes or granules 49 
Stearyl Alcohol Practically insoluble Waxy flakes or granules 59 
Cetostearyl 
alcohol 
Practically insoluble Waxy flakes or granules 48-55 
Table 4.3: Pharmaceutical Fatty Alcohols with Properties Similar to Magnesium Stearate. 
Chemical properties adapted from (31). 
 
Component Aqueous Solubility 
Physical Form 
@ Room Temperature 
Melting 
Point (°C) 
Myristic Acid Practically Insoluble Waxy solid 54.5 
Palmitic Acid Practically Insoluble Powder 63-64 
Stearic Acid Practically Insoluble Powder 69-70 
Table 4.4: Pharmaceutical Fatty Carboxylic Acids with Properties Similar to Magnesium 




Component Aqueous Solubility 
Physical Form 
@ Room Temperature 
Melting 
Point (°C) 
Glyceryl Monostearate Practically Insoluble Waxy Solid 55-60 
Glyceryl Behenate Practically Insoluble Powder 65-77 
Glyceryl Palmitostearate Practically Insoluble Powder 52-55 
Table 4.5: Pharmaceutical Glyceryls with Properties Similar to Magnesium Stearate. Chemical 
properties adapted from (31). 
 
Component Aqueous Solubility 
Physical Form 
@ Room Temperature 
Melting 
Point (°C) 
Magnesium Stearate Practically Insoluble Powder 126-130 
Calcium Stearate Practically Insoluble Powder 149-160 
Zinc Stearate Practically Insoluble Powder 120-122 
Aluminum Monostearate Practically Insoluble Powder 220-225 
Aluminum Distearate Practically Insoluble Powder 150-165 
Aluminum Tristearate Practically Insoluble Powder 117-120 
Table 4.6: Pharmaceutical Stearates with Properties Similar to Magnesium Stearate (Including 
Magnesium Stearate). Chemical properties adapted from (31). 
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Component Aqueous Solubility 
Physical Form 
@ Room Temperature 
Melting 
Point (°C) 
Ascorbyl Palmitate Practically Insoluble Powder 107-117 
Sodium Stearyl Fumarate 1 in 20,000 Powder 224-225 
Menthol Practically insoluble Powder 34 
Table 4.7: Other Pharmaceutical Excipients with Properties Similar to Magnesium Stearate. 
Chemical properties adapted from (31). 
 




Deferasirox and etravirine active pharmaceutical ingredients were sourced from Teva Active 
Pharmaceutical Ingredients (Teva TAPI, Petah Tikva, Israel). Copovidone, glyceryl 
monostearate, and crospovidone were sourced from BASF (BASF, Ludwigshafen, Germany). 
Glyceryl dibehenate was sourced from Gattefosse (Gattefosse, Paramus, NJ, USA). Sodium 
stearyl fumarate, microcrystalline cellulose, and aerosil were sourced from FMC Biopolymer 
(FMC, Philadelphia, PA, USA). Ascorbyl palmitate, stearic acid, stearyl alcohol, menthol, cetyl 
alcohol, menthol, sodium acetate, sodium chloride, sodium hydroxide, monobasic sodium 
phosphate monohydrate, and hydrochloric acid were sourced from Fisher Scientific (Hampton, 
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NH, USA). Magnesium stearate was sourced from Mutchler (Harrington Park, NJ, USA). 
Hypromellose capsules size 00EL were sourced from Capsugel (Capsugel, Morristown, NJ, 
USA). Hypromellose methocel E5 was sourced from Dow (Petaluma, CA, USA). Vitamin E 
polyethylene glycol succinate was sourced from Antares (Ewing Township, NJ, USA). Mannitol 
was sourced from Millipore Sigma (Millipore Sigma, St. Louis, MO, USA). FaSSGF, FaSSIF, 
FeSSIF powder was sourced from Biorelevant (Biorelevant.com, London, UK). Ritonavir was 
sourced from a confidential supplier. PEG 8000 was sourced from Letco Medical (Decatur, AL, 
USA).  
 
4.3.2 X-Ray Diffraction Analysis for All Samples: 
 
Powder X-ray diffraction was performed on a MiniFlex 600 XRD unit (Rigaku, The Woodlands, 
TX, USA). Samples were loaded into metal sample holders and leveled prior to analysis. The 
instrument was configured with a Cu alpha radiation tube and was operated at 40 kV and 15 mA. 
The detector was a D/teX Ultra unit. A scan speed of 5.0 degrees/minute was used with a step 
size of 0.02 degrees across a range of 2-30 2theta. PDXL software package was used for data 
analysis (Rigaku, The Woodlands, TX, USA). 
 
4.3.3 KinetiSol Processing of DFX-Lubricant Examples: 
 
Samples containing deferasirox, copovidone, and an appropriate lubricant were processed into 
amorphous solid dispersions by KinetiSol processing. Formulation information is contained in 
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Table 4.8. Materials were dispensed into a plastic bag and mixed by hand for at least 1 minute. 
10 grams of sample blend was loaded into a KBC20 KinetiSol Research Formulator (DisperSol 
Technologies, Georgetown, TX, USA) and processed at 7000 rpm to an ejection temperature of 
150°C. Ejected material was manually quenched between two metal plates into an amorphous 
sheet. The amorphous material was milled in an IKA tube mill 100 (IKA, Staufen, Germany) at 
5000 rpm in 30 second intervals. Between intervals, samples were passed through a No. 60 mesh 
screen (250 µm) with the coarse particles recycled into the tube mill. All samples processed until 
fully milled and all samples were confirmed as x-ray amorphous by the XRD method previously 
described.
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Component Lot 2 Lot 3 Lot 4 Lot 5 Lot 6 Lot 7 Lot 8 Lot 9 Lot 23 Lot 25 
Deferasirox (DFX) 50 50 50 50 50 50 50 50 50 50 
Copovidone 49 49 49 49 49  49 49 50 49 
Glyceryl dibehenate 1          
Sodium stearyl fumarate  1         
Ascorbyl palmitate   1        
Stearic acid    1       
Stearyl alcohol     1      
Menthol      1     
Glyceryl monostearate       1    
Cetyl alcohol        1   
Magnesium stearate          1 
Table 4.8: Formulation Information for DFX-Lubricant Compositions Processed by KinetiSol. Numerical Values are % w/w.
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4.3.4 Dissolution Testing of Deferasirox-Lubricant Examples: 
 
Dissolution testing was performed on Distek 2500 dissolution system (Distek, North Brunswick, 
NJ, USA). The unit was configured as Apparatus 2 with paddle speed at 50 rpm. 750 mL of 50 
mM sodium acetate buffer, pH 5 was added to each vessel and heated to 37°C. 150 mg of 
deferasirox amorphous intermediate was loaded into size 00EL hypromellose capsules. One 
capsule per sample was dropped into each vessel using stainless steel sinkers just prior to test 
initiation. A Spectra fiber optic UV-Vis probe (Pion Inc, Billerica, MA, USA) monitored drug 
concentration in solution with data points collected every 5 minutes for 4 hours total run time. A 
wavelength of 295 nm was used for data acquisition with a baseline correction of 400 nm. Data 
was analyzed by AU Pro software (Pion Inc., Billerica, MA, USA). 
 
4.3.5 KinetiSol Processing and Tableting of Etravirine-Lubricant Examples: 
 
Samples containing etravirine, hypromellose E5, and vitamin E polyethylene glycol succinate 
with sodium stearyl fumarate in one iteration were processed into amorphous solid dispersions 
by KinetiSol processing. Formulation information is contained in Table 4.9. Materials were 
dispensed into a plastic bag and mixed by hand for at least 1 minute. 100 grams of sample blend 
was loaded into a KBC250 KinetiSol Batch Compounder (DisperSol Technologies, Georgetown, 
TX, USA) and processed at 2500 rpm to an ejection temperature of 170°C. Ejected material was 
quenched in a pneumatic chill press (DisperSol Technologies, Georgetown, TX, USA) into an 
amorphous sheet. The amorphous material was milled in a L1A Fitzmill (Fitzpatrick, Waterloo, 
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ON, CA) at 9000 rpm with hammers forward and passed through a 250 µm screen. All samples 
were confirmed as x-ray amorphous by the XRD method previously described. 
 
Component Lot 30025 Lot 30026 
Etravirine (ETV) 20 20 
Hypromellose, E5 grade (HPMC E5) 75 74 
Vitamin E Polyethylene Glycol Succinate (TPGS) 5 5 
Sodium stearyl fumarate (SSF) 0 1 
Table 4.9: Formulation Information for Amorphous Solid Dispersions Containing Etravirine and 
With or Without Sodium Stearyl Fumarate. Numerical values are % w/w. 
 
Tablet blends were prepared per Table 4.10 with amorphous intermediate screened through a 125 
µm screen. Tablets were compressed using a single-station automated tablet press and were 




Component Lot 30025 Lot 30026 
Etravirine (ETV) 14.29 14.29 
Hypromellose, E5 grade (HPMC E5) 53.57 52.86 
Vitamin E Polyethylene Glycol Succinate (TPGS) 3.57 3.57 
Sodium stearyl fumarate (SSF) 0.00 0.71 
Mannitol 10.00 10.00 
Microcrystalline cellulose 10.00 10.00 
Crospovidone 7.07 7.07 
Colloidal silicon dioxide 0.50 0.50 
Magnesium stearate 1.00 1.00 
Table 4.10: Formulation Information for Tablets Containing Etravirine Amorphous Solid 
Dispersions With or Without Sodium Stearyl Fumarate. Numerical values are % 
w/w. 
 
4.3.6 Dissolution Testing of Etravirine-Lubricant Examples: 
 
Dissolution testing was performed on Vankel 7000 dissolution system (Agilent, Santa Clara, CA, 
USA). The unit was configured as Apparatus 2 with paddle speed at 70 rpm. FaSSIF dissolution 
media was prepared per the procedure provided with the FaSSGF, FaSSIF, and FeSSIF powder 
and with sodium chloride, sodium hydroxide, and monobasic sodium phosphate monohydrate as 
salts for the buffer precursor preparation. 900 mL of FaSSIF media was added to each vessel and 
heated to 37°C. One tablet per sample was dropped into each vessel just prior to test initiation. 
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100 mg and 200 mg tablets were used in dissolution testing. A Spectra fiber optic UV-Vis probe 
(Pion Inc, Billerica, MA, USA) monitored drug concentration in solution with data points 
collected every 5 minutes for 6 hours total run time. A wavelength of 310 nm was used for data 
acquisition with a baseline correction at 380 nm. Data was analyzed by AU Pro software (Pion 
Inc., Billerica, MA, USA). 
 
4.3.7 In-Vivo Pharmacokinetic Analysis of Etravirine-Lubricant Examples: 
 
An in-vivo pharmacokinetic study was conducted in fasted male beagle dogs at Charles Rivers 
Laboratories (Charles Rivers, Wilmington, MA, USA). Each animal was dosed with one 25 mg 
tablet followed by a 40 mL sterile water flush by oral gavage. Five dogs were used per arm. At 
time points of 0.5, 1, 1.5, 2, 3, 4, 6, and 12 hours, 1 mL of whole blood was collected with 
sodium heparin as an anticoagulant. Plasma was isolated and analyzed by a bioanalytical LC-
MS/MS method for etravirine concentration. Pharmacokinetic analysis was conducted by 
Watson pharmacokinetic software (Fisher Scientific, Hampton, NH, USA). 
 
4.3.8 Melt-Quenching of Ritonavir-Lubricant Examples: 
 
In suitably sized beakers, PEG 8000 was slowly heated with stirring from an overhead impeller 
until fully melted. With stirring, ritonavir and sodium stearyl fumarate (when applicable) were 
slowly added to the melted PEG 8000 per the formulations summarized in Table 4.11. 
Composition was stirred with slight heat until a clear solution was formed. The melted 
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dispersions were dispensed into chilled pans to rapidly quench. Material collected from the pan 
was milled to form powder with an IKA tube mill 100 (IKA, Staufen, Germany) at 5000 rpm for 
30 second intervals. Between intervals, sample was passed through a No. 60 mesh screen (250 
µm) with the coarse particles recycled into the tube mill. All samples processed until fully 
milled. All samples were confirmed as x-ray amorphous with respect to ritonavir by the XRD 
method previously described. 
 
Component Lot 13 Lot 14 
Ritonavir (RTV) 30 30 
Polyethylene Glycol (PEG 8000) 70 69 
Sodium Stearyl Fumarate (SSF) 0 1 
Table 4.11: Formulation Information for Amorphous Solid Dispersions Containing Etravirine 
and With or Without Sodium Stearyl Fumarate. Numerical values are % w/w. 
 
4.3.9 Dissolution Testing of Ritonavir-Lubricant Examples: 
 
Dissolution testing was performed on Distek 2500 dissolution system (Distek, North Brunswick, 
NJ, USA). The unit was configured as Apparatus 2 with paddle speed at 50 rpm. 750 mL of 0.1N 
hydrochloric acid was added to each vessel and heated to 37°C. 333 mg of ritonavir amorphous 
intermediate representing 100 mg of ritonavir was dispersed on the surface of the dissolution 
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media. Three vessels were analyzed per test article. At time points of 10, 20, 30, 45, and 60 
minutes, 5 mL of sample was sampled by cannula and filtered through 0.45 µm PVDF syringe 
filters with glass membrane pre-filters. Filtered samplers were diluted 1:1 with acetonitrile and 
transferred to HPLC vials after mixing. An isocratic water/acetonitrile HPLC method was used 
for analysis with an Acclaim™ 120, C18, 5µm, 120A, 4.6x150mm, P/N: 059148 (Thermo Fisher 
Scientific, Waltham, MA, USA) HPLC column for separation. The ritonavir peak was analyzed 




4.4.1 X-ray Powder Diffraction: 
 
All samples analyzed were fully x-ray amorphous except for the ritonavir/PEG-8000 solid 
dispersions. Peaks associated with PEG-8000’s crystalline structure were observed, but no peaks 




The dissolution figures for deferasirox amorphous solid dispersions with various lubricants are 
shown in Figure 4.5. The sample containing magnesium stearate as the additive had the highest 
release, followed by a cluster of release profiles that contained glyceryl dibehenate, sodium 
stearyl fumarate, ascorbyl palmitate, stearic acid, stearyl alcohol, glyceryl monostearate, and 
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cetyl alcohol. The sample without lubricant released to lower extent than the cluster followed by 
the sample that contained menthol which exhibited the lowest overall release. 
 
 
Figure 4.5: Dissolution Testing of Amorphous Solid Dispersions Containing Deferasirox and 






























Glyceryl dibehenate Sodium stearyl fumarate Ascorbyl palmitate
Stearic acid Stearyl alcohol Menthol
Glyceryl monostearate Cetyl alcohol None
Magnesium stearate
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4.4.3 Etravirine-Sodium Stearyl Fumarate with a Surfactant: 
 
The dissolution figures for 100 and 200 mg etravirine tablets with and without sodium stearyl 
fumarate in the amorphous solid dispersion are shown in Figures 4.6a and 4.6b. For both tablet 
strengths, the sample containing sodium stearyl fumarate in the amorphous solid dispersion 
released to a greater extent and maintained a higher degree of supersaturation than the sample 
that did not contain sodium stearyl fumarate in the amorphous solid dispersion. 
 
 
Figure 4.6: Dissolution Profiles for Etravirine from Tablets With (30026) and Without (30025) 





Figure 4.6, cont. 
 
Etravirine blood plasma concentrations in the in-vivo pharmacokinetic study in fasted male 
beagle dogs is shown in Figure 4.7. The pharmacokinetic parameters are summarized in Table 
4.12. The blood concentration reached an average Cmax of 433 ng/mL in the dogs dosed with 
the tablets that included sodium stearyl fumarate in the amorphous solid dispersion and to a 
Cmax of 327 ng/mL in the dogs dosed with the tablets did not include sodium stearyl fumarate. 
Similarly, AUC0-12 was 2486 ng*hr/mL in the sample with sodium stearyl fumarate and 2079 





Figure 4.7: Etravirine Plasma Concentration for Pharmacokinetic Analysis of 25 mg Etravirine 
Tablet With (30026) and Without (30025) Sodium Stearyl Fumarate 
 
Parameter 30025 30026 
Cmax (ng/mL) 327 ± 120 433 ± 147 
Tmax (hr) 2.2 ± 0.6 2.4 ± 0.9 
AUC0→12 (ng*hr/mL) 2,080 ± 581 2,486 ± 946 
Table 4.12: Summary of Pharmacokinetic Parameters for Analysis of Etravirine Tablets With 
(30026) and Without (30025) Sodium Stearyl Fumarate 
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4.4.4 Ritonavir-Sodium Stearyl Fumarate by Melt Quenching: 
 
The dissolution profiles for the ritonavir-PEG 8000 solid dispersions are shown in Figure 4.8. 
The sample that contained sodium stearyl fumarate exhibited a faster release rate and a greater 




Figure 4.8: Dissolution Profiles for Ritonavir-PEG 8000 Melt-Quench Amorphous Solid 
































For amorphous solid dispersions of deferasirox, in-vitro dissolution performance was enhanced 
for nearly all lubricants evaluated (see Figure 4.5). For all of these enhanced results, dissolution 
rate and concentration at 4 hours was higher than the sample that lacked a lubricant. These 
results substantiated the in-vivo pharmacokinetic result for deferasirox and magnesium stearate 
previously described. Deferasirox is a weak acid molecule and this example represents the 
opportunity to apply this formulation approach to other molecules in this classification. While 
weak acids are not as commonly benefitted by amorphous solid dispersions due to their increased 
solubility in media resembling intestinal pH (22), deferasirox is administered at high doses (>30 
mg/kg) (23) and solubility enhanced formulations can reduce patient pill burden while 
maintaining overall exposure. (24) 
 
In-vitro solubility enhancement was observed for stearyl alcohol, cetyl alcohol, stearic acid, 
glyceryl dibehenate, glyceryl monostearate, magnesium stearate, sodium stearyl fumarate, and 
ascorbyl palmitate. These positive results demonstrated the advantage of included fatty alcohols, 
fatty carboxylic acids, glyceryls, and stearates in amorphous solid dispersions for solubility 
benefits. By contrast, menthol represented a negative case in which in-vitro performance was 
diminished after its addition. While menthol shares many properties in common with the other 
entities explored, it lacks fatty acid chains present in all other examples. This likely speaks to the 
important role of the fatty chain to the performance of the amorphous solid dispersions. 
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Interestingly, magnesium stearate demonstrated a boosted effect beyond that observed for the 
other lubricants evaluated. Of note is that magnesium stearate possesses two fatty acid chains per 
molecule due to the +2 charge of the magnesium metal ion. However, this effect was not 
investigated further in this study. 
 
4.5.2 Etravirine-Sodium Stearyl Fumarate with a Surfactant: 
 
For amorphous solid dispersions containing etravirine and the lubricant sodium stearyl fumarate, 
both in-vitro and in-vivo performance enhancement were observed over the same formulation 
without lubricant in the amorphous solid dispersion (Figures 4.6a and 4.6b). During in-vitro 
analysis, drug release rate was faster for tablets containing amorphous solid dispersions with 
sodium stearyl fumarate and a higher dissolution Cmax was observed. Thus, the lubricant aided 
in spring portion of the spring-parachute model for the system. (25) Additionally, the tablets with 
sodium stearyl fumarate in the amorphous solid dispersion appeared to reach equilibrium 
concentrations of about 18% release and 9.5% release in the 100 mg and 200 mg tablets 
respectively. By contrast, the tablets without sodium stearyl fumarate appeared to not be at 
equilibrium after 6 hours of analysis with release values of approximately 14% and 6.5%, 
respectively, and declining. The higher in-solution concentration and achievement of equilibrium 
demonstrates the value of the sodium stearyl fumarate lubricant as an effective solubility 
maintaining parachute for etravirine. In the in-vivo pharmacokinetic analysis shown in Figure 4.7 
and Table 4.12, the tablet with 1% sodium stearyl fumarate in the amorphous solid dispersion 
had 32% greater Cmax and 19.5% greater AUC0-12 than the tablet with the formulation that did 
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not include the lubricant in the amorphous solid dispersion. The positive results observed during 
in-vitro analysis translated to the in-vivo analysis. 
 
At pharmaceutically relevant pH, etravirine is a non-ionic molecule with pH independent 
solubility. (26) These results suggest that lubricants can be applied to this classification of non-
ionic drug molecules as well. Interestingly, the benefit was observed in a system where solubility 
was already expected to be benefitted by the inclusion of the tradition surfactant. (27) This result 
represents the advantage of a lubricant even for formulations benefitted by a surfactant. Finally, 
the demonstrated performance gains are both for in-vitro solubility enhancement and in-vivo 
drug absorption. 
 
4.5.3 Ritonavir-Sodium Stearyl Fumarate by Melt-Quenching: 
 
For the amorphous solid dispersion containing ritonavir and sodium stearyl fumarate, superior 
in-vitro dissolution performance was observed when compared to a formulation that did not 
include sodium stearyl fumarate in the dispersion (see Figure 4.8). The sample containing 
sodium stearyl fumarate released much more rapidly than the sample without sodium stearyl 
fumarate. 91% of observed release occurred by the 10 minute time point for sodium stearyl 
fumarate sample compared to 71% at the same time point. Additionally, 24% higher in-solution 
concentration was observed for the sodium stearyl fumarate sample compared to the one without 
lubricant at the 1 hour time point of dissolution analysis. Release rate and extent of ritonavir in 
0.1N hydrochloric acid has been shown to correlate well with in-vivo results for ritonavir:PEG 
8000 amorphous solid dispersions. (28) 
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This positive example for the weakly basic ritonavir molecule represents the potential value of 
including lubricants in amorphous solid dispersions for the weakly basic compounds. Weak base 
molecules are of high interest for development into amorphous solid dispersions due to their 
inherently poor aqueous solubility at intestinal absorption sites. (29, 30) Of note is that prior 
examples were generated with KinetiSol processing, but this ritonavir:PEG 8000 system utilized 
melt-quenching to process the material into an amorphous solid dispersion. Melt quenching (or 
melt cooling) can be used to represent fusion based processes such as hot-melt extrusion or 
KinetiSol processing. (4) Thus, a successful result with a lubricant via the melt-quench process 
lends itself to the expectation that inclusion of a lubricant would benefit other fusion based 
processes. As mentioned previously, solvent processing of amorphous solid dispersions 
containing lubricants would represent a significant challenge as these components are practically 




As a result of the work conducted in this study, it was concluded that inclusion of lubricants 
internally in an amorphous solid dispersion can be utilized as a tool for enhancing the in-vitro 
and in-vivo performance of poorly water soluble drugs. The benefit was observed in drug 
molecules that represented weak acid, neutral, and weak base compounds. Lubricants that 
presented a performance advantage include fatty alcohols, fatty acids, glyceryls, stearates, 
sodium stearyl fumarate and ascorbyl palmitate. The performance advantage was observed in 
systems that included a traditional surfactant which promises the opportunity to use lubricants in 
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conjunction with systems that contain these components. Successful demonstration by melt-
quenching in addition to KinetiSol processing showed that the process was applicable to a 
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